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Abstract
Maintenance of optimal gene expression levels is critical for cell viability and homeostasis. However,
misregulation of gene expression can and regularly occur. One type of detrimental misregulation involves
overexpression of a single gene that can cause organismal death is dosage sensitivity, which is often due to
increased concentration of the protein encoded by the gene. Deleterious increases in the expression of specific
proteins are associated with various neurodegenerative diseases such as Parkinson’s and Alzheimer’s Diseases
as well as other cellular maladies including various cancers and Down Syndrome. In yeast, it has been
estimated that ~20% of genes are toxic when overexpressed. The physicochemical properties and function of a
protein seem to dictate whether it will be toxic upon overexpression. However, the mechanism by which
individual proteins become toxic when overexpressed is typically unclear, which complicates the development
of agents that counter toxicity of diverse dosage-sensitive genes. The overarching goal of this thesis was to
rationally engineer a ‘buffer’ that universally mitigates the toxicity of dosage-sensitive genes.
To meet this goal, we turned to Hsp104, a hexameric, ring-shaped AAA+ ATPase and protein-remodeling
factor found in yeast, which protects yeast from toxicity associated with aggregated and misfolded proteins
induced by chemical, heat, or age-related stress. An engineered variant of Hsp104, Hsp104A503S, displayed
potentiated activity and suppressed proteotoxicity of various neurodegenerative disease proteins, including
TDP-43, FUS, and α-synuclein in yeast, whereas wild-type Hsp104 was ineffective. Inspired by this striking
activity, we determined whether Hsp104A503S could combat the toxicity of diverse yeast dosage-sensitive
genes. Surprisingly, Hsp104A503S suppressed the toxicity of nearly 98% of dosage-sensitive genes tested,
whereas wild-type Hsp104 rescued none. Expression of Hsp70- or Hsp90-class chaperones also failed to
suppress toxicity of the majority of dosage-sensitive genes. To achieve this broad rescue of dosage-sensitive
genes, Hsp104A503S required critical tyrosines in pore-loops that engage substrate during protein
remodeling and translocation across the central channel of Hsp104. Moreover, ATPase activity at NBD1 or
NBD2 was required for Hsp104A503S to alleviate toxicity of dosage-sensitive genes. Rescue of toxicity by
Hsp104A503S was not typically due to decreases in toxic protein expression or disaggregation of amyloid. In
addition, neither autophagy nor proteasome activity was required for Hsp104A503S to rescue the toxicity of
dosage-sensitive genes. Rather, Hsp104A503S effectively prevented the formation of labile, SDS-soluble
aggregates, which correlated with alleviation of toxicity. With null mutants, we established that the intrinsic
function of several dosage-sensitive kinases and phosphatases was crucial for overexpression toxicity. In vitro
functional assays with Ppz1 (a dosage-sensitive protein phosphatase), indicated the phosphatase activity was
reduced by Hsp104A503S and not by Hsp104. Lastly, we demonstrated that Hsp104A503S suppressed the
toxicity of the potent oncogenic kinase, v-Src, in yeast, decreasing protein levels and kinase activity in yeast.
Thus, we suggest that in addition to preventing formation of labile, SDS-soluble aggregates Hsp104A503S can
also suppress dosage sensitivity by directly unfolding or otherwise deactivating toxic protein such as Ppz1 and
v-Src. These studies establish that potentiated protein-remodeling factors like Hsp104A503S can serve as a
powerful buffer that mitigates the toxicity of nearly all dosage-sensitive yeast genes.
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ABSTRACT 
 
POTENTIATED HSP104 VARIANTS SUPPRESS THE TOXICITY OF MOST 
OVEREXPRESSED DOSAGE-SENSITIVE YEAST GENES 
Michael Yancey Soo 
James Shorter, Ph.D. 
 
Maintenance of optimal gene expression levels is critical for cell viability and 
homeostasis. However, misregulation of gene expression can and regularly occur. One 
type of detrimental misregulation involves overexpression of a single gene that can 
cause organismal death is dosage sensitivity, which is often due to increased 
concentration of the protein encoded by the gene. Deleterious increases in the 
expression of specific proteins are associated with various neurodegenerative diseases 
such as Parkinson’s and Alzheimer’s Diseases as well as other cellular maladies 
including various cancers and Down Syndrome. In yeast, it has been estimated that 
~20% of genes are toxic when overexpressed. The physicochemical properties and 
function of a protein seem to dictate whether it will be toxic upon overexpression. 
However, the mechanism by which individual proteins become toxic when 
overexpressed is typically unclear, which complicates the development of agents that 
counter toxicity of diverse dosage-sensitive genes. The overarching goal of this thesis 
was to rationally engineer a ‘buffer’ that universally mitigates the toxicity of dosage-
sensitive genes. 
To meet this goal, we turned to Hsp104, a hexameric, ring-shaped AAA+ ATPase 
and protein-remodeling factor found in yeast, which protects yeast from toxicity 
associated with aggregated and misfolded proteins induced by chemical, heat, or age-
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related stress. An engineered variant of Hsp104, Hsp104A503S, displayed potentiated 
activity and suppressed proteotoxicity of various neurodegenerative disease proteins, 
including TDP-43, FUS, and α-synuclein in yeast, whereas wild-type Hsp104 was 
ineffective. Inspired by this striking activity, we determined whether Hsp104A503S could 
combat the toxicity of diverse yeast dosage-sensitive genes. Surprisingly, Hsp104A503S 
suppressed the toxicity of nearly 98% of dosage-sensitive genes tested, whereas wild-
type Hsp104 rescued none. Expression of Hsp70- or Hsp90-class chaperones also 
failed to suppress toxicity of the majority of dosage-sensitive genes. To achieve this 
broad rescue of dosage-sensitive genes, Hsp104A503S required critical tyrosines in pore-
loops that engage substrate during protein remodeling and translocation across the 
central channel of Hsp104. Moreover, ATPase activity at NBD1 or NBD2 was required 
for Hsp104A503S to alleviate toxicity of dosage-sensitive genes. Rescue of toxicity by 
Hsp104A503S was not typically due to decreases in toxic protein expression or 
disaggregation of amyloid. In addition, neither autophagy nor proteasome activity was 
required for Hsp104A503S to rescue the toxicity of dosage-sensitive genes. Rather, 
Hsp104A503S effectively prevented the formation of labile, SDS-soluble aggregates, which 
correlated with alleviation of toxicity. With null mutants, we established that the intrinsic 
function of several dosage-sensitive kinases and phosphatases was crucial for 
overexpression toxicity. In vitro functional assays with Ppz1 (a dosage-sensitive protein 
phosphatase), indicated the phosphatase activity was reduced by Hsp104A503S and not 
by Hsp104. Lastly, we demonstrated that Hsp104A503S suppressed the toxicity of the 
potent oncogenic kinase, v-Src, in yeast, decreasing protein levels and kinase activity in 
yeast. Thus, we suggest that in addition to preventing formation of labile, SDS-soluble 
aggregates Hsp104A503S can also suppress dosage sensitivity by directly unfolding or 
otherwise deactivating toxic protein such as Ppz1 and v-Src. These studies establish 
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that potentiated protein-remodeling factors like Hsp104A503S can serve as a powerful 
buffer that mitigates the toxicity of nearly all dosage-sensitive yeast genes. 
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CHAPTER 1: BACKGROUND AND SIGNIFICANCE 
1.1 Proteins, Folding, and Misfolding 
Proteins are essential building blocks of life and are required for almost every 
process a living organism must undertake including growth, reproduction, responding to 
stimuli or threats, and metabolizing nutrients. Other than water, no molecules are more 
abundant in the cell than proteins (1) Proteins also exhibit incredible diversity. There are 
about 30,000 protein-coding genes in the human genome, of which over 90% can be 
alternatively spliced to yield hundreds of thousands of splice variants, each of which 
could yield a unique protein if translated (2). As such, every organism must carefully 
control every aspect of the process of protein production from transcribing DNA into 
RNA, splicing pre-mRNA, and translating the transcript into polypeptide strings featuring 
20 amino acids in various combinations, which provide the foundation for virtually every 
protein on earth. 
As proteins are synthesized by the ribosome, the different amino acids within the 
polypeptide chain interact with each other to form stable interactions, folding the protein 
into intricate three-dimensional structures to achieve the “native”, active confirmation. 
However, some proteins are intrinsically disordered, featuring solvent-exposed regions 
that do not form stable intramolecular interactions (3, 4). Even though the instructions for 
how each protein folds into its native state are encoded in the primary amino acid 
sequence, protein folding is a difficult, dynamic process and most proteins do not 
instantaneously adopt their native structure but take a meandering route (5, 6). The first 
step of protein folding is a hydrophobic collapse in which the hydrophobic residues 
quickly bind to each other to form a molten globule that excludes water from the core of 
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the protein, which maximizes entropy of the water solvent (7-9). The protein then begins 
to form secondary and tertiary structure, navigating towards the lowest energy 
conformation, which can be an arduous process with many possible pathways and off-
target diversions for a protein to take through a potentially rugged energetic landscape to 
reach the natively folded state (10) (Fig. 1). For large proteins with multiple domains, this 
process can be especially difficult because as the protein folds, it forms many 
intermediates that may not contribute to the final conformation. Moreover, in the 
exceedingly crowded cytoplasm, the nascent polypeptide is bombarded with different 
interacting binding partners such as lipids, nucleic acids, small molecules, and other 
proteins (11).  
Once the protein reaches the native state it constantly undergoes conformational 
changes to execute its function. Protein functionality often demands a dynamic structure 
that must explore different conformations to maximize activity. These various 
conformations may only be marginally stable and place the protein at risk for misfolding 
or aggregation (12). Moreover, thermodynamics dictate that a protein population at 
equilibrium will feature proteins that are fully folded, partially folded, misfolded, and even 
completely unfolded following a Boltzmann distribution where the lowest energy states 
for the protein will have a higher probability of being occupied but all states from native 
to completely disordered are populated (13). Furthermore, in the human proteome, 
approximately half of all proteins are predicted to contain intrinsicially-disordered regions 
that are permanently unfolded and nearly a quarter of total proteins are predicted to be 
completely disordered (3). 
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Figure 1: Protein-folding energy landscape.  
Protein folding takes place within a free energy landscape in which the protein must 
navigate to reach the native folded state. Intermediates that become trapped in local 
minima must overcome energy barriers to reach the final conformation. Cellular 
chaperones in the cell help guide folding towards the native state, prevent aberrant 
intermolecular interactions that can lead to amorphous aggregate or amyloid fibril 
formation, and can disaggregate and unfold aggregated proteins to enable refolding to 
the native state. (Adapted with permission from Elsevier, License Number: 
3944940299836) (14) 
 
Because protein folding is such a dynamic process, rife with obstacles, many 
proteins require the aid of accessory proteins, termed chaperones, which aid in their 
proper folding (Fig. 1) (15-18). The requirement for chaperones is especially acute if 
proteins contain multiple domains requiring complex architectural organization. From the 
moment a nascent polypeptide exits the ribosome, protein chaperones engage the 
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protein to facilitate folding (19-21). While small, single-domain proteins fold rapidly in 
vivo and in test tubes, large multi-domain proteins often fold poorly in isolation, 
generating partially folded intermediates and misfolded conformations, that often expose 
hydrophobic regions that can promote self-association into aggregates (22). The 
geometry of the ribosome and speed of protein translation dictates that folding can 
typically not be completed until the entire sequence has emerged from the ribosomal 
polypeptide exit channel (20, 21). To promote proper folding, emerging polypeptides are 
immediately bound by molecular chaperones that associate with the ribosome, including 
trigger factor in prokaryotes or nascent chain-associated complex (NAC) in eukaryotes 
(20, 21, 23). These chaperones associate with the nascent protein and prevent 
formation of aberrant inter- and intra-protein interactions until the polypeptide chain exits 
the ribosome, thereby preventing improper folding. Chaperones of the classical Hsp70 
system, DnaK and DnaJ in bacteria and Hsp70 and Hsp40 in eukaryotes, can also 
associate with these nascent proteins while still emerging from the ribosome to facilitate 
folding (24-26). In humans, there are over a dozen Hsp70 and Hsp40 genes, each family 
member has their own substrate-binding preference and function in protein folding, 
refolding, disaggregation, and transferring substrates to other downstream processes if 
the client protein remain non-native (14, 25-27). These downstream processes could 
include unfolding and refolding by the chaperonin system, GroEL and GroES in bacteria 
or TRiC in eukaryotes (25, 26), the folding and maturation of clients by the Hsp90 
system (28, 29), degradation by the ubiquitin proteasome system (30, 31), or 
disaggregation of aggregated substrates by the Hsp100 or Hsp110 systems (32-35).  
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1.2 Gene Overexpression and Its Causes 
Cells have developed highly integrated systems for maintaining protein 
homeostasis to ensure proper synthesis, folding, localization, and turnover in the 
crowded cellular environment where macromolecular concentration can be as high as 
300 mg/ml (most of which is protein) (11, 19). However, misregulation of gene 
expression can and does occur. One example is the overexpress of a protein-coding 
gene that can lead to an overabundance of the encoded protein. While many genes are 
well-tolerated when expressed at high levels natively or are greatly induced in response 
to stimuli or stress, aberrant overexpression of certain genes can lead to a wide variety 
of human disease and disorders including Parkinson’s Disease (PD) (36-38), Charcot-
Marie-Tooth neuropathy (39), and a multitude of cancers (40, 41). This proteostatic 
balance is so delicate that the increase in copy number of a single gene encoding α-
synuclein, SNCA, can be the sole cause of some cases of PD (36). Aside from gene 
duplication, increased gene dosage can be due to a variety of sources including 
aneuploidy, chromosome translocation, activation of transcription factors, and defects in 
protein degradation systems (42, 43).  
1.2.1 Aneuploidy 
Most eukaryotic organisms are diploid, possessing two homologous sets of 
chromosomes, usually one from each parent. During cell division, new sets of 
chromosomes must be synthesized from the existing chromosome and then segregated 
equally between daughter cells during cell division. Aneuploidy is the condition when this 
process is not accurately carried out, resulting in the abnormal increase or decrease in 
the number of chromosomes. In most cases, the disruption to the cell caused by 
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aneuploidy is so severe that it leads to cells that are unable to grow, develop, or 
continue through the cell cycle (44). The cause of the growth defect is likely due to a 
confluence of factors including broad-spectrum transcriptome perturbations, effects on 
expression of genes on other chromosomes, and an increased burden to the 
transcription, translation, chaperone, and protein degradation systems (45). 
Increases or decreases in the number of chromosomes can lead to altered 
organismal fitness likely due to changes in gene expression. Microarray transcriptome 
profiling in yeast lacking or containing an extra chromosome show that protein 
expression levels are often correlated with copy number changes of that gene due to 
aneuploidy (44, 46). In general, organisms are less able to accommodate losses in 
whole chromosomes, due to decreases in the expression of essential proteins and 
disruption of protein stoichiometry (47). However, gene dosage increases of most 
individual genes, does not result in severe growth defects, rather loss of fitness in 
organisms with extra chromosomes is likely due to the accumulation of multiple small 
defects, where increased amounts of extra genetic material is correlated with the 
decreases in proliferation (46). In the case of additional chromosomes, the additive 
effect of many small changes in protein stoichiometry likely results in loss of fitness. 
Organisms often attempt to compensate for increases in gene copy and subsequent 
elevation of transcript levels by decreasing protein expression through suppression of 
translation or increased degradation (48-51). This dependence on increased protein 
degradation is supported by findings that show yeast with extra chromosomes are more 
sensitive to proteasome inhibitors (46) and cancer cells, which are often aneuploid, also 
exhibit increased sensitivity to proteasome inhibitors (52). 
One of the most well-known human examples of aneuploidy, is Trisomy 21 in 
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which three copies of the twenty-first chromosome (HSA21) instead of two causes Down 
Syndrome (DS) (53). Even though HSA21 is the smallest chromosome in the human 
genome, containing only around 300 expressed genes, a single extra copy can lead to 
widespread physical, developmental, and intellectual deficits (54, 55). The 
supernumerary chromosome causes a 50% average increase in expression of all genes, 
but expression is variable on a gene and tissue-specific level with some genes not 
overexpressed at all and others overexpressed over 1.5-fold (56). Phenotypic mapping 
has been used to determine the genes that underpin specific defects in DS, but one 
gene on HSA21 not associated with DS but with other health implications is the Amyloid 
Precursor Protein gene, APP (55). APP produces a precursor protein that is then 
cleaved into Amyloid-beta: a peptide that forms fibrillar amyloid plaques in the brains of 
Alzheimer’s Disease (AD) patients. Interestingly, nearly all brains of deceased DS 
patients over 30 years of age featured amyloid plaques similar to those found in AD 
patients and DS patients often present with similar neurological defects such as loss of 
language skills and ultimately dementia (57, 58). Accumulations of Amyloid-beta plaques 
and tau tangles developed two to three decades earlier with three-fold higher rate of 
diagnosed dementia in DS patients compared to the non-DS population (57, 58). 
Moreover, another neurodegenerative disease associated gene, Cu/Zn superoxide 
dismutase (SOD1), is also located on the HSA21. A DS patient with SOD1 mutation 
leading to ALS was identified, although overexpression of SOD1 is not generally 
considered to be a mechanism of ALS pathogenesis (59). 
Many cancers and tumors with increased growth and proliferation phenotypes 
feature aneuploidy (60, 61). This correlation is not necessarily causative but can be an 
indication of the lack of genomic control (62). Indeed, aneuploidy can be both a cause 
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and an effect of cancer. Several lines of evidence suggest that aneuploidy is not 
causative of tumorigensis and is the result of increased rate cell proliferation that can 
lead to loss of genomic integrity (46, 63, 64). On the other hand, there are clear 
examples where aneuploidy can be oncogenic, which specific genes that are 
overexpressed can be transforming (65-69). Studies in yeast have shown that 
aneuploidy can be advantageous under some circumstances, where it can alter 
transcription profiles to quickly adapt to changing environmental conditions and stress 
(70, 71). The instability of the genome in cancer cells may allow them to rapidly explore 
aneuploid states for phenotypes that would be most beneficial as host cells attack the 
cancer (72, 73). In cancer, aneuploidy is can be context specific, with overexpression of 
some genes promoting tumor formation in certain cell types while inhibiting it in others, 
but the relative chromosomal instability allows rapid access to variant proteome profiles 
that can be potentially advantageous in specific cancer cell niches and can even confer 
drug resistance (74). However, the aneuploid nature of many cancer cells might enable 
evolutionary traps, which predictably shift the population into a druggable space that 
could be readily eliminated (75). 
1.2.2 Chromosome Translocations 
 Chromosome translocations are another alteration in genomic integrity, which is 
caused by rearrangement of nonhomologous chromosome that can result in the 
misregulation of gene expression (76). Chromosome translocations occur when a 
segment of one chromosome is fused to a nonhomologous chromosome or a new site 
on the same chromosome (77). Translocations require double-stranded DNA breaks at 
two separate chromosomal locations, activation of cellular DNA repair machinery, 
followed by anomalous fusion and repair to create novel chromosomes. Depending on 
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the location of the chromosomal lesions and the genes that are affected, disruption and 
misregulation of gene function can occur. 
One of the first characterized chromosome translocations was in the Philadelphia 
chromosome of some chronic myelogenous leukemia (CML) patients, in which the short 
arms of chromosomes 9 and 22 are switched (78, 79). This translocation created a novel 
fusion protein due to the fusion of the ABL1 gene, originally on chromosome 9, to BCR 
on chromosome 22 (80). Further study on BCR-ABL identified the fusion to be an 
oncogene in which the kinase activity of ABL was constitutively active, stimulating 
proliferation of myeloid cells leading to CML (81). In other cases, translocations do not 
result in gene fusions, but instead replace the coding sequence of one gene with another 
so that the promoter and enhancer sequences of one gene therefore regulate another. 
The first characterized example of this phenomenon was in Burkitt’s lymphoma patients, 
in which c-MYC, which regulates the expression of thousands of genes (82, 83), from 
chromosome 8 was placed under the control of the highly induced immunoglobulin 
heavy-chain gene promoter region on chromosome 14 (84-86). In a contemporary study, 
c-MYC was also found to be similarly translocated in mouse plasmacytomas, where it 
was also placed under control of an immunoglobulin gene promoter (87-90). The result 
of these translocations was loss of regulated, temporal induction of c-MYC replaced with 
constitutive, high overexpression, and carcinogensis. 
Since the characterization of the oncogenic translocations in the 1980’s, over 
60,000 chromosomal aberrations, of which over 10,000 are gene fusions, have been 
reported in nearly every cancer type (91). However, chromosome translocation events 
associated with lymphomas and leukemia can be found in normal individuals and 
present a real cellular challenge that needs to be overcome because the consequences 
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for failure to combat these can be dire for the organism (92). 
1.2.3. Transcription Factor Activation 
Perturbations to transcription factors (TFs) are a common avenue that can lead 
to gene misregulation and overexpression. TFs are proteins that control which genes are 
expressed by binding to specific, regulatory DNA sequences near the target genes to 
stimulate or repress expression (93, 94). Alone or in concert with other proteins, TF 
binding to DNA influences the engagement of the RNA polymerase II machinery to the 
target DNA, acting either as an activator that recruits RNA polymerase II to transcribe 
the gene, or as a repressor that blocks RNA polymerase II binding and thus transcription 
(94). TF regulation of the genome is essential. TFs control the repertoire of genes that 
are expressed, which is how every cell in our bodies, despite having the same copies of 
DNA, can express different genes and have vastly different phenotypes (95, 96). The 
most common gene mutated in cancer cells is p53, a TF that acts as a tumor suppressor 
when activated by stress, inducing expression of genes that can arrest cell cycle 
progression, induce apoptosis, and repair DNA damage (97). 
TFs canonically have two separate, modular domains, a DNA-binding domain 
(DBD) that binds specific DNA sequences corresponding to enhancer, repressor, or 
promoter regions and a trans-activating domain (TAD) that allows for interaction with 
other regulatory proteins and the transcription initiation complex (93). TFs may also 
contain stimulus-response domains, which upon phosphorylation or binding to ligands 
induces a conformational change that activates or deactivates the TF (98, 99). Mutations 
to the DBD, TAD, or regulatory regions can lead to changes in the activation of TFs that 
can therefore drastically change the composition of the transcriptome (100, 101). The 
DBDs of most TFs are relatively short small regions approximately 20-30 amino acids in 
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length that bind relatively short DNA sequences that are typically 6-12 bases long (102). 
The amino acid composition of the DBD dictates the nucleotide sequences it will bind, 
thus mutations to the DBD will affect the strength and stringency of the interaction, the 
tolerance for binding modified DNA, and the structural context of the DNA (103, 104). 
Single amino acid mutations in the DBD can greatly affect the DNA sequences the TF 
can bind to and thus the genes that are expressed. This effect is especially striking 
because most TFs are pleiotropic and can influence a large number of genes, one of the 
most interesting of which is Pdr1 in yeast (105). PDR1, for “pleiotropic drug resistance,” 
was discovered in a survey of yeast strains where mutations in the gene were 
discovered to confer resistance to up to 18 different small-molecule drugs with 
mitochondrial and non-mitochondrial targets, including the fungicides oligomycin, 
Antimycin A, and cycloheximide (106, 107). Characterization of these PDR1 mutations 
revealed loss of inhibition and constitutive activation, loss of DNA binding and thus 
inactivation, changes in the binding preference for DNA leading to a change in genes 
induced, or perturbations in the TAD that leads to differential protein binding and 
alterations downstream gene activation (108, 109).  
1.2.4. Defects in Protein Degradation 
 As proteins are being synthesized, they are also constantly turned over, 
hydrolyzed by proteases back to amino acids to be reused again (14, 110). The rates of 
degradation vary from minutes to months depending on the individual role of each 
protein in the cell and are carefully balanced with rate of synthesis (110). Most proteins 
are degraded by the ubiquitin-proteasome system (UPS) (111) or by lysosomes via 
autophagy (112, 113). In the UPS, ubiquitin is used as a signaling molecule that marks 
proteins to be targeted for proteasomal degradation (14, 110). An E1-ubiquitin activating 
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enzyme primes the ubiquitin, which is then transferred to an ubiquitin-conjugating 
enzyme that along with a E3-ubiquitin ligase covalently attaches the ubiquitin to a lysine 
or the N-terminus of a targeted protein (114, 115). Polyubiquitylation can then occur on 
lysine 48 of ubiquitin to produce a tag to identify proteins for proteasomal degradation 
(14, 110). The proteasome is an elaborate, barrel-shaped protein holoenzyme consisting 
of a proteolytic 20S core particle of four stacked heptameric rings that is flanked by a 
regulatory 19S particle comprise of base and lid substructures, which unfold and 
deubiquitylate substrates prior to entry into the proteolytic chamber for degradation (116, 
117). Proteins can also be degraded by delivery to the lysosome by chaperone-mediated 
autophagy or macroautophagy. Autophagy is especially crucial for aggregates and 
misfolded proteins that may not be degraded by the UPS. Chaperone-mediated 
autophagy (CMA) is the selective degradation of protein substrates in the lysosome 
(118). In CMA, specific protein substrates are recognized by the heat shock protein, 
Hsc70, which targets the substrate to the lysosome surface where the protein is then 
translocated into the lysosomal matrix for degradation (119). In macroautophagy, excess 
or damaged organelles and entire protein aggregates can be sequestered in double 
membrane vesicles called autophagosomes, which then fuse with lysosomes for 
degradation and recycling of biosynthetic constituents (120). 
Several human diseases feature increased levels of pathogenic proteins due to 
deficiencies in the protein degradation pathway including α-synuclein in PD. α-Synuclein 
is a small, 140-residue, membrane-associated protein found in the pre-synapse of 
neurons (121, 122). While the normal function of the protein is not fully understood 
(122), α-synuclein is notable for its formation of beta-sheet rich amyloid fibrils in Lewy 
neurites in the processes of synaptic neurons and Lewy bodies in cell bodies of neurons, 
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the defining hallmark of PD and other related neurodegenerative diseases termed 
synucleinopathies (123-125). Several uncommon mutations as well as gene duplication 
have been discovered to lead to heritable cases of PD (36, 121, 126, 127), but in 
general most instances are sporadic (128, 129). Characterization of purified α-synuclein 
has shown that it is predominantly unfolded and intrinsically disordered in solution (130, 
131). These intrinsically disordered regions present an opportunity to form deleterious 
interactions that can lead to aggregation (132, 133). In post-mitotic neurons, where 
regulation of homeostasis is crucial, several defects were found in the UPS and 
autophagy pathways of PD patients, which included reduced proteasome activity and 
downregulation of proteasome components in PD patient tissues, and alterations in 
proteasome and autophagy function in a rat models of PD (134). Moreover, α-synuclein 
has been demonstrated to be targeted for CMA degradation, and CMA defects have 
been described in both familial and sporadic PD (135-137). Additionally, studies with 
transgenic animals and neurons expressing α-synuclein have found that proteasome 
inhibition resulted in accumulation of α-synuclein in dopaminergic neurons and 
accelerated neurodegeneration phenotypes (138-140). Furthermore, other studies in PD 
patients have found increases in the number of autophagasomes in affected neurons 
(141) as well as decreases in the lysosomal markers suggested accumulation of α-
synuclein in dysfunctional autophagosomes (142, 143). 
c-Myc is another example of a UPS substrate in which a failure in degradation 
can lead to inappropriate accumulation and ultimately oncogenesis. c-Myc is a proto-
oncogene that encodes a transiently expressed TF with a normally short half-life of 
around 30 minutes in cellsb(144, 145). Phosphorylation at threonine 58 and serine 62 
are important for ubiquitylation and degradation by the proteasome (146, 147). However, 
 14 
 
mutations to Thr58 or Ser62 in c-Myc that prevent phosphorylation or in kinases that 
phosphorylate these residues can result in a significant decrease in the ubiquitylation 
and degradation, leading to accumulation of active c-Myc (148, 149). c-Myc activation of 
downstream pathways can lead to rapid cell proliferation and also enhancement of 
transformation phenotypes. 
1.3 Mechanisms for Dosage Sensitivity Toxicity 
The mechanism for toxicity due to gene overexpression and dosage sensitivity 
has been the subject of much debate. Initially, Hurst and colleagues proposed the 
“balance hypothesis” in which imbalances in the concentration of subcomponents of 
protein-protein complexes are deleterious (Fig. 2A) (150). Thus, underexpression or 
overexpression of protein complex subunits would confer toxicity. Indeed, several lines 
of evidence suggest that the balance hypothesis helps explain reduced fitness due to 
underexpression and haploinsufficiency. For example, yeast genes connected with low 
heterozygote fitness tend to be in protein complexes (150, 151). The specific topological 
arrangements of protein within a complex is an accurate predictor of underexpression 
toxicity (152). However, the balance hypothesis has been less able to provide a 
compelling explanation of overexpression toxicity of yeast genes where many toxic 
proteins are not components of large protein complexes (4, 151). Moreover, in yeast 
there is little overlap between genes that are toxic when overexpressed and haplo-
insufficient genes (42). With the exception of a small set of essential genes, in which the 
overexpression phenotype mirrors the deletion phenotype and the overexpressed 
protein is known to be a member of multi-subunit complexes, altered protein complex 
stoichiometry is not likely the root cause for most instances of overexpression lethality 
(4, 42, 151).  
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Specific regulatory imbalances appear to be the primary cause of overexpression 
toxicity rather than disruption of protein complex stoichiometry (4, 42, 151). At least 
~80% of yeast genes are not toxic when overexpressed (4, 42). However, proteins that 
are toxic at elevated concentrations due to overexpression tend to have intrinsically 
disordered, low-complexity domains (4). Mass-action-driven interaction promiscuity due 
to intrinsically disordered, low-complexity domains within proteins has emerged as a 
leading theoretical framework to explain why certain protein-coding genes are toxic 
when overexpressed (4). In addition, hyperactive gene function (e.g. kinase or 
phosphatase activity) is likely important for toxicity of a number of dosage-sensitive 
genes (Fig. 2D). The presence of intrinsically disordered, low-complexity domains within 
toxic proteins indicates that protein misfolding and potentially aggregation could play a 
key role in overexpression toxicity (4, 153). Thus, a novel gain-of-function could arise 
due to toxic soluble oligomer formation or aggregate formation (Fig. 2B) (154, 155). 
However, intrinsically disordered, low-complexity domains also participate in functional 
liquid-liquid phase separation (LLPS) events that underpin the formation of various 
membraneless organelles (156-159). Thus, overexpression could lead to inappropriate 
or excessive LLPS, which might also be toxic (Fig. 2E) (160). Finally, sequestration of 
essential proteins or chaperones, and loss of negative feedback and regulation might 
also contribute to overexpression toxicity (Fig. 2F) (42, 43, 161, 162). 
Toxic aggregate formation and accumulation is perhaps the easiest to 
understand of the mechanisms that cause dosage sensitivity (Fig. 2B). The fact that 
dosage-sensitive proteins are generally enriched for unfoldedness, long unfolded 
regions, long transcripts, and slow transcription rates suggests that these proteins are 
not well folded in their native state and when overexpressed could overwhelm the 
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proteostasis network and lead to aberrant aggregate formation that the cell cannot 
abrogate (4). Alternatively, these proteins may adopt soluble but toxic oligomeric 
conformations like numerous human neurodegenerative disease proteins (163, 164). 
Indeed, almost all human neurodegenerative disease proteins contain intrinsically 
disordered regions (155, 165, 166). Aberrant oligomerization and aggregation is thought 
to be the mechanism for the toxicity of a number of human neurodegenerative diseases, 
including ALS, PD, AD, and Creutzfeldt–Jakob disease (167-170). 
Another hypothesis for overexpression toxicity is that the toxic protein does not 
aggregate but sequesters essential proteins and chaperones via mass-action-driven 
interaction promiscuity (4). Dosage-sensitive proteins tend to be enriched in unfolded 
regions, which likely increases the burden on the endogenous chaperone machinery. In 
essence, overexpressing certain high-burden protein substrates would bind protein 
chaperones preventing them from acting on their native substrates, some of which could 
be essential, resulting in a net loss of function of certain proteins (Fig. 2F). This type of 
dosage sensitivity is not specific to the function of the protein but could potentially be 
mimicked by any large influx of highly unfolded protein that demanded the attention of 
the protein chaperone system. In addition, misfolded and aggregated proteins with 
exposed hydrophobic regions and other residues not usually solvent accessible in the 
native conformation could foster aberrant interactions with other soluble proteins, which 
can remove these proteins from their proper localization or inhibit their functionality (Fig. 
2C). 
A probable explanation for the mechanism of dosage sensitivity of certain 
proteins is related to the intrinsic activity of the protein itself. The cell is a fine-tuned 
machine, which requires all processes to be highly controlled and regulated. For 
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example, protein kinases phosphorylate substrate proteins and protein phosphatases 
exist to regulate kinase activity by removing phosphates ligated to substrates. Similarly, 
fatty acid synthases that create triglycerides to store energy as fat are opposed by 
lipases that aid in the digestion of the dietary lipids to allow absorption of catabolized 
nutrients. In almost all cases, pairs or groups of proteins exist that oppose the function of 
their respective counterparts. However, when the expression of a specific protein is 
drastically increased, the cell may not be able to regulate this activity because without 
upregulation of its counteracting partner, the overexpressed protein is now 
unencumbered in its activity which can lead to defects in growth (Fig. 2D). This 
regulatory imbalance can lead to anomalous phosphorylation of proteins, abnormal 
activation of genes by TFs, or deleterious depletion of resources, all of which can be 
ultimately fatal for the organism. 
In this vein, TFs are among the most toxic genes when overexpressed, with more 
than double the rate of dosage sensitivity compared to the rest of the genome (42). 
Nearly a third of TFs were reported to be dosage sensitive, which makes sense because 
TF overexpression can lead to subsequent upregulation of other genes unleashing a 
cascade of aberrant gene overexpression. Indeed, TF overexpression often results in 
perturbations of known physiological functions and specific expression activation or 
repression of their target genes (171). Moreover, TFs often bind to characterized 
regulatory DNA sequence motifs proximal to their target genes affecting their expression 
patterns (171). TF overexpression leads to the induction of known targets and shows 
that overexpression can increase occupancy of TF to their known targets (171). The fact 
that overexpression of TFs causes growth defects suggests that their increased activity 
may result in pathway activation and dysregulation that results in deleterious 
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transcriptome imbalances. 
The physicochemical properties and function of a protein seem to dictate whether 
it will be toxic upon overexpression. However, the mechanism by which individual 
proteins become toxic when overexpressed has typically not been delineated, and as 
illustrated above, diverse mechanism may be responsible. This mechanistic diversity 
complicates the development of agents that counter toxicity of diverse dosage-sensitive 
genes. Indeed, is it even possible to define a single, wide-reaching solution for genes 
that are harmful and can cause disease when overexpressed? The answer seemed to 
be “no” because the mechanisms by which genes might be deleterious when 
overexpressed are numerous and diverse. However, because Hsp104 is able to unfold 
many proteins that can be damaged during cellular stress, it seemed to be a promising 
candidate to pursue. 
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Figure 2: Possible mechanisms of dosage sensitivity.  
A. Overexpression of one component of a multi-protein complex can lead to loss of 
stoichiometric balance and formation of nonfunctional intermediates. The phenotype 
overexpression phenotype for these types of proteins may be the same as gene 
deletion. B. Overexpression of intrinsically disordered or aggregation-prone proteins 
could lead to the formation of toxic soluble oligomers or large aggregates. C. 
Overexpression of toxic aggregation-prone proteins could lead to aggregates that form 
non-native interactions with soluble protein and remove them from the cytosol. D. 
Overexpression of a kinase (e.g. kinase in blue) could lead to overactive kinase activity 
leading to excessive phosphorylation (yellow star) of a substrate (light green) resulting in 
increased downstream signaling. Without commensurate upregulation of the 
endogenous phosphatase (dark green), hyperphosphorylation is left unchecked. E. 
Overexpression of proteins with intrinsically unfolded, low-complexity regions can lead to 
generation of liquid-liquid phase separations (LLPS) events which may be toxic. F. 
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Overexpression of difficult-to-fold substrates could lead to sequestration of chaperones 
and subsequent misfolding of other proteins, some of which could be essential for 
viability. 
 
1.4 Hsp104 is a Potent Protein-Remodeling Factor and Protein Disaggregase 
In the brewer’s yeast Saccharomyces cerevisiae, Hsp104 is a hexameric, ring-
shaped AAA+ (ATPases associated with diverse cellular activities) protein and a potent 
protein-remodeling factor and protein disaggregase of the Hsp100 family (172, 173). It is 
an essential protein for yeast to tolerate diverse stresses and is greatly induced following 
low and high temperature shock and chemical stresses (173). Unlike most protein 
chaperones like Hsp40, Hsp70, and Hsp90 that facilitate folding of nascent polypeptides, 
the primary function of Hsp104 is to disaggregate and refold stress-induced, aggregated 
and misfolded proteins, returning these proteins back to their native form (32, 174, 175). 
Its aggregated substrates in yeast can include a diverse set of structures from 
amorphous aggregates formed during heat shock to highly-ordered, fibrillar amyloids of 
a single species like the Sup35, Rnq1, and Ure2 prions that underpin the non-Mendelian 
elements [PSI+], [RNQ+], and [URE3+], respectively (176-179). However, Hsp104 
activity is not restricted to just aggregated substrates. Hsp104 is also a powerful protein-
remodeling factor capable of disassembling soluble toxic oligomers formed by diverse 
proteins (177, 180-182). Hsp104 can also convert intrinsically disordered prion domains 
into self-replicating prion conformers under certain conditions (177, 180). Finally, 
Hsp104 can act as an unfoldase, which under some circumstances (e.g. in vitro in the 
presence of ATP and ATPγS) unfold natively-folded proteins like GFP provided they are 
appended to an intrinsically disordered domain (183). 
 Hsp104 is a member of the Hsp100 family of molecular chaperones, which 
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contain highly conserved AAA+ domains that utilize the energy from ATP hydrolysis to 
remodel protein substrates (184, 185). Hsp104 contains two AAA+, nucleotide-binding 
domains (NBD1 and NBD2), a middle domain (MD) separating the two NBDs, and an N-
terminal domain (NTD) and C-terminal domain (CTD) flanking the NBD1 and NBD2 
respectively (Fig. 3A). Hsp104 forms barrel-shaped hexamer in vivo, in which the NTD, 
and the two NBDs form a set of three stacked rings surrounding a hollow central pore 
through which substrate is translocated (Fig. 4) (186, 187). Recent studies show that the 
Hsp104 can adopt an asymmetric helical architecture with the AAA+ domains forming a 
two-turn spiral around the central pore axis (Fig. 3B) (188). The NTD is involved in 
substrate specification and engagement, and enables optimal disaggregase activity 
(189). Once engaged, the protein substrate is subsequently bound to conserved 
substrate-binding tyrosines on pore loops inside the channel in each of the NBDs (190, 
191). Hsp104 utilizes ATP hydrolysis to translocate the protein through the central pore 
thus unfolding it (Fig. 4) (174, 190, 191). The MD can regulate Hsp104 activity by 
forming autoinhibitory interactions with NBD1 to repress the activity of the protein and by 
establish inter-protomer bridges across the nucleotide-binding pocket to control ATP 
hydrolysis and thus Hsp104 function (188, 192, 193). The role of the CTD is not as well 
understood, but it is require for the hexamerization of Hsp104 (194). 
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Figure 3: Domain architecture and structure of Hsp104. 
A. Domain architecture of Hsp104 with corresponding residues. B. Multiple views from a 
3D density map of Hsp104 obtain by Cryo-EM. The domains, shaded the same colors as 
in part A, are arranged in a left-handed, three-tiered spiral with an asymmetric seam 
between the first and sixth protomer of the hexamer. Axial and longitudinal dimensions 
of the whole protein (black) and the central pore (grey) are given. (Adapted with 
permission from Nature Publishing Group, License Number: 3944951097151) (188). 
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Figure 4: Model of Hsp104 disaggregation of diverse substrates.  
Hsp104 in collaboration with Hsp40s and Hsp70s, binds a wide variety of substrates 
including amorphous aggregates and highly-ordered aggregates through interactions in 
the N-terminal domain (NTD). The protein substrates are translocated through the 
central pore of Hsp104 where substrate-binding tyrosines on pore loops in the two 
nucleotide-binding domains (NBD1, NDB2) powered by ATP hydrolysis provide the 
locomotive force to unfold and thread the substrate through the hexamer to solution. 
 
In yeast, Hsp104 is crucial for the disaggregation and maintenance of proteins 
that are associated with aging. Deletion of Hsp104 resulted in an accelerated aging 
phenotype and reduction in longevity (195). As organisms age, protein homeostasis 
integrity declines in all aspects from diminished chaperone activity, increased amounts 
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of misfolded and aggregated protein, and decreased proficiency of protein degradation 
systems (15, 196-199). This deficiency in maintaining proteostasis combined with 
increasing amounts of oxidative stress (200, 201) can result in the accumulation of toxic 
protein that further exacerbates the aging phenotype (202, 203). Yet, despite its 
seemingly indispensible function in preserving proteostasis and limiting the effects of 
aging, Hsp104 homologs are not conserved in the metazoan lineage of evolution. 
Indeed, although conserved in eubacteria, some archaebacteria, and the vast majority of 
eukaryotes including all fungi, plants, protozoa, and algae, Hsp104 is conspicuously 
absent in animals (204, 205). Although some Hsp104 functions are preserved in other 
molecular chaperones complexes, notably the Hsp110, Hsp70, and Hsp40 system (35), 
the loss of Hsp104 is highly puzzling considering the myriad benefits it bestows upon the 
host. Considering the greatest risk factors for human neurodegenerative disease is 
aging (206), this lack of Hsp104 presented an opportunity for designing and introducing 
bespoke Hsp104 variants that can target aggregation-prone proteins, especially those 
implicated in several incurable human neurodegenerative disease (207-210).  
 
1.5 Engineering Potentiated Hsp104 Variants 
Encouragingly, Hsp104 is well tolerated in metazoan systems and can 
collaborate with mammalian Hsp110, Hsp70, and Hsp40 molecular chaperones to 
remodel aggregated protein (35). Furthermore, wild-type Hsp104 has the ability to 
remodel the protein aggregates and mitigate the symptoms associated with ALS (211), 
PD (182), AD (212), and HD (213-216) in animal models of human neurodegenerative 
disease. Moreover, Hsp104 can disaggregate a diverse panel of amyloid fibrils formed 
by neurodegenerative disease proteins (181). However, this ability to cure 
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neurodegenerative disease phenotypes is limited and in some cases, Hsp104 may 
actually enhance toxicity of some disease-associated proteins (217). To improve on the 
native function of Hsp104, genetic variants of Hsp104 were systematically generated 
and screened in yeast for the ability to suppress toxicity of TDP-43 and FUS, each 
implicated in ALS and Frontotemporal Lobar Degeneration (FTLD), and also α-
synuclein, which has an active role in the development of PD (207-210). Compared to 
Hsp104, which had limited efficacy in suppressing disease protein toxicity, many of the 
mutants generated were far more effective (207-209).  
An uncovered Hsp104 variant that was one the best suppressors of α-synuclein, 
TDP-43, and FUS toxicity in yeast contained an A503V mutation (Hsp104A503V) (207-
210). The A503 is in helix 3 of the coiled-coil, middle domain of Hsp104, which is 
important for ATPase activity, coordination of NBD1 and NBD2 activity, disaggregation, 
and forming interactions with Hsp70 that can promote protein disaggregation (192). 
Given its crucial role in regulating so many processes and interaction, it is perhaps not 
surprising that previous studies of MD variants found that mutations in this region could 
be toxic to the organism or also have beneficial gain-of-function phenotypes (218). 
Mutational characterization found that nearly all mutations at the 503 position enhanced 
Hsp104 suppression of toxicity to varying degrees and only A503P had no effect or 
increased toxicity of the toxic disease-associated proteins (207). Hsp104A503V was able 
to suppress toxicity and aggregation of α-synuclein, FUS, and TDP-43 in yeast restoring 
solubility and proper localization, without drastically decreasing toxic protein expression 
and independent of the unfolded protein response and autophagy pathways (207). 
Hsp104A503V and Hsp104A503S could also disaggregate preformed α-synuclein, FUS, and 
TDP-43 fibrils in vitro at concentrations where Hsp104 was inactive (207). Hsp104A503S, 
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which has very similar activity to Hsp104A503V, was tested in a C. elegans model of PD 
(207). In this PD nematode model, human α-synuclein is overexpressed in the 
dopaminergic neurons, resulting in severe neurodegeneration, which worsens as the 
animals age (219). Hsp104A503S co-expression in the dopaminergic neurons was 
protective, significantly increasing the number of worms with the complete complement 
of dopaminergic neurons (207). Biochemical studies of in vitro purified Hsp104A503V 
demonstrated that compared to Hsp104, Hsp104A503V exhibited elevated ATPase rate, 
superior disaggregation function even without Hsp70 and Hsp40, improved substrate 
translocation efficiency, and the enhanced ability to unfold soluble protein (207). 
The significant efficacy of Hsp104A503S in mitigating the toxicity of several dosage-
sensitive human neurodegenerative disease proteins in yeast and α-synuclein in a 
nematode model of PD led us to interrogate the extent of the buffering capacity of 
Hsp104A503S. Thus, we tested Hsp104A503S against a battery of dosage-sensitive yeast 
proteins to obtain a more global picture of the repertoire of toxic proteins Hsp104A503S 
can rescue. 
1.6. Overarching Goal of Thesis. 
The overarching goal of this thesis was to rationally engineer a ‘buffer’ that 
universally mitigates the toxicity of dosage-sensitive genes, i.e. genes that are toxic 
when overexpressed. By introducing the A503S mutation into Hsp104, we have 
engineered an enhanced protein-remodeling factor that antagonizes the toxicity of a 
remarkable number of dosage-sensitive genes. The results of my studies are presented 
in the next chapter. 
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CHAPTER 2: SUPPRESSING DOSAGE LETHALITY WITH HSP104A503S 
2.1 Introduction 
Hsp104A503S was very effective at suppressing the toxic aggregation phenotypes 
in our yeast neurodegenerative disease models in which disease-associated proteins 
(e.g. TDP-43, FUS, or α−synuclein) are overexpressed (207-210). Thus, we investigated 
the ability of Hsp104A503S to combat dosage sensitivity caused by overexpression of 
endogenous yeast proteins. We hypothesized that if overexpression of some proteins 
causes proteostatic stress due to the formation of soluble toxic oligomers, toxic 
aggregates, or inappropriate liquid-liquid demixing phase transitions, then Hsp104A503S 
should be able to disassemble these toxic species and suppress the deleterious effect of 
dosage sensitivity. Dosage-sensitive screens have been used to determine substrates of 
proteins such as kinases, phosphatase, transcription factors, and other proteins (42, 
220), as well as dissect complex pathways such as kinetochore assembly, chromosome 
segregation, establishing cell polarity, histone regulation of transcription, and cell cycle 
progression (221-224). We overexpressed genes that caused a growth defect in yeast, 
to identify genes whose toxicity was suppressed by Hsp104A503S. We predicted these 
genes would code for protein substrates that Hsp104 could directly bind, disaggregate or 
remodel, and detoxify. We expected Hsp104 to have a limited capacity to suppress 
dosage-sensitive proteins because of its restricted ability to combat the most toxic 
human disease-associated proteins in our yeast models, but Hsp104A503S would be able 
to suppress a greater number of dosage-sensitive genes because in the same context it 
has proven to be more effective (207-210). Because dosage-sensitive proteins and 
many aggregation-prone disease proteins commonly have large portions that are 
unfolded and disordered (4), we further postulated that Hsp104A503S would engage these 
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toxic proteins through their exposed, unstructured low-complexity domains, and unfold 
the complete toxic protein via ATPase-coupled translocation across the central Hsp104 
channel. This coupled unfoldase and translocase activity would also unfold monomeric 
soluble protein, disassemble soluble toxic oligomers, disaggregate aggregated 
structures, and denature toxic conformers. Moreover, the increased ATPase activity of 
Hsp104A503S enables it to complete its reaction cycle more rapidly (207). Thus, we 
expected Hsp104A503S to be a significantly more robust inhibitor of dosage sensitivity 
because it would be able to remodel more toxic substrates than Hsp104 per unit time. In 
essence, we suspected that the hyperactive protein-remodeling activity of Hsp104A503S 
would be extremely beneficial when cells are challenged with the overexpression of a 
single toxic protein. 
2.2 Results 
2.2.1 Hsp104A503S but Not Hsp104 Suppressed Most Instances of Dosage 
Sensitivity 
We previously screened the FLEXGene overexpression plasmid library (225) for 
candidate genes that were toxic when overexpressed in the BY4741 yeast strain in both 
the wild-type background and with HSP104 deleted. We did not find a substantial 
number of genes with significant difference in toxicity when expressed in the wild-type 
background compared to Δhsp104. From those hits we created a small library of 198 
plasmids containing genes marked as potentially dosage-sensitive (Table 1). Each gene 
was individually arrayed onto a 96-well tissue culture plate to be used in high-throughput 
yeast transformations. In this study, each plasmid was individually transformed into 
Δhsp104 yeast to create strains containing an empty pAG413Gal vector (BYV), 
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pAG413Gal-Hsp104 (BYW), or pAG413Gal-Hsp104A503S (BYA) to determine if either 
Hsp104 or Hsp104A503S overexpression could suppress the toxicity of each induced 
dosage-sensitive gene (Fig. 5A). The pAG413Gal plasmid system was chosen for 
expressing Hsp104 because the centromeric element ensures a relatively consistent, 
low copy number per cell (1-2), the Gal1-10 promoter produces robust inducible 
expression with galactose-containing media (and strong repression on glucose to enable 
routine passage of yeast), and the HIS3 gene allowed for positive selection of the 
plasmid in BY4741 yeast. The toxicity of each dosage-sensitive gene in the BYV, BYW, 
and BYA yeast strains was scored on a scale of 0 to 5, with 0 corresponding to no 
toxicity and 5 corresponding to full toxicity and no growth (Fig. 5B). Confirming previous 
results (207), Hsp104A503S strongly suppressed the toxicity of α-synuclein, FUS, and 
TDP-43 (Fig. 5C). 
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Table 1: Dosage-sensitive genes screened for Hsp104A503S suppression.  
These 198 genes were selected after a previous genome-wide screen in BY4741 for 
potential dosage sensitivity. Systematic and standard names are given for each gene. 
Systematic Standard Systematic Standard Systematic Standard Systematic Standard 
YLR220W CCC1 YHR206W SKN7 YKR092C SRP40 YNL186W UBP10 
YDR151C CTH1 YIL045W PIG2 YDR143C SAN1 YDR436W PPZ2 
YPL145C KES1 YHR124W NDT80 YHR046C INM1 YJL128C PBS2 
YLR136C TIS11 YGL071W AFT1 YOR032C HMS1 YPL203W TPK2 
YML113W DAT1 YIL055C YIL055C YDR303C RSC3 YIL131C FKH1 
YPL021W ECM23 YHR050W SMF2 YBR073W RDH54 YHR115C DMA1 
YPL071C YPL071C YOR008C SLG1 YDR310C SUM1 YGR276C RNH70 
YLR073C YLR073C YLR228C ECM22 YNL233W BNI4 YIL036W CST6 
YGL096W TOS8 YMR298W LIP1 YPL128C TBF1 YOR195W SLK19 
YDR113C PDS1 YOR188W MSB1 YLR096W KIN2 YDR216W ADR1 
YLR013W GAT3 YOR058C ASE1 YOL124C TRM11 YDR251W PAM1 
YNL074C MLF3 YOR156C NFI1 YDR395W SXM1 YGR140W CBF2 
YMR257C PET111 YGL216W KIP3 YPL202C AFT2 YIL119C RPI1 
YOL104C NDJ1 YER125W RSP5 YIL031W ULP2 YBL097W BRN1 
YMR258C YMR258C YLR347C KAP95 YDR159W SAC3 YPL212C PUS1 
YGL003C CDH1 YGL016W KAP122 YKL166C TPK3 YOL112W MSB4 
YPL269W KAR9 YPR181C SEC23 YLR341W SPO77 YNL108C YNL108C 
YGR109C CLB6 YMR179W SPT21 YJL042W MHP1 YKR004C ECM9 
YBL054W YBL054W YNL224C SQS1 YER129W SAK1 YBL103C RTG3 
YBL029W YBL029W YAL031C GIP4 YBL107C YBL107C YNL076W MKS1 
YBR182C SMP1 YDR306C YDR306C YGL049C TIF4632 YJL013C MAD3 
YPL270W MDL2 YOR113W AZF1 YMR219W ESC1 YER133W GLC7 
YDL088C ASM4 YBR273C UBX7 YPL137C GIP3 YBR049C REB1 
YJL069C UTP18 YOL006C TOP1 YCL048W SPS22 YCR091W KIN82 
YGL224C SDT1 YCL056C YCL056C YPL190C NAB3 YGL190C CDC55 
YDL155W CLB3 YPL248C GAL4 YNL020C ARK1 YNR031C SSK2 
YNL047C SLM2 YER169W RPH1 YML068W ITT1 YER047C SAP1 
YPL255W BBP1 YER167W BCK2 YHR172W SPC97 YBL063W KIP1 
YNL311C SKP2 YDR293C SSD1 YFR023W PES4 YLL003W SFI1 
YPL153C RAD53 YPR120C CLB5 YHR086W NAM8 YML010W SPT5 
YLR057W YLR057W YML016C PPZ1 YOL027C MDM38 YDR103W STE5 
YNL188W KAR1 YML081W YML081W YPR065W ROX1 YOL089C HAL9 
YGL162W SUT1 YDR430C CYM1 YBL009W ALK2 YPR119W CLB2 
YDL224C WHI4 YKR021W ALY1 YHR177W YHR177W YGR249W MGA1 
YLR241W YLR241W YDR393W SHE9 YAL025C MAK16 YNR034W SOL1 
YMR153W NUP53 YHR082C KSP1 YIL105C SLM1 YKL068W NUP100 
YOR329C SCD5 YML034W SRC1 YDR505C PSP1 YNL091W NST1 
YMR032W HOF1 YDR212W TCP1 YLR026C SED5 YPL070W MUK1 
YEL009C GCN4 YDR096W GIS1 YKL089W MIF2 YPR147C YPR147C 
YPL115C BEM3 YHR070W TRM5 YBR179C FZO1 YMR111C YMR111C 
YBR250W SPO23 YJR132W NMD5 YBR059C AKL1 YBR289W SNF5 
YOL105C WSC3 YOL013C HRD1 YKR096W YKR096W YFL037W TUB2 
YKR052C MRS4 YJL092W HPR5 YBR156C SLI15 YDR335W MSN5 
YBL031W SHE1 YML031W NDC1 YPL237W SUI3 YGL150C INO80 
YCL029C BIK1 YOR212W STE4 YPR104C FHL1 YDL233W YDL233W 
YPL184C MRN1 YMR182C RGM1 YFL016C MDJ1 YER164W CHD1 
YGL122C NAB2 YBR083W TEC1 YAR042W SWH1 YGL073W HSF1 
YGR083C GCD2 YHR098C SFB3 YDR356W SPC110 YDL195W SEC31 
YLR253W YLR253W YIL006W YIA6 YHR084W STE12   
YBR158W AMN1 YLR332W MID2 YNL183C NPR1   
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Figure 5: Protocol for screening and scoring dosage-sensitive genes.  
A. An overexpression plasmid library of potentially dosage-sensitive genes was 
screened to determine which toxic yeast genes could be suppressed by Hsp104 or 
Hsp104A503Sexpression. The transfected yeast were serially diluted and plated on 
Glucose (control) and Galactose-containing (overexpression) plates. Toxic genes that 
were strongly suppressed (yellow star) by Hsp104A503S, weakly suppressed (red star), or 
not suppressed at all (blue star) were identified. B. Genes were scored on a toxicity 
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scale from 0 to 5, with 5 corresponding to the greatest toxicity (BIK1) and 0 for genes 
with no toxicity (UTP18). C. Human neurodegenerative disease proteins, TDP-43, FUS, 
and α-synuclein were expressed with an empty vector, Hsp104, and Hsp104A503S 
coexpression (n = 4 independent transformations). 
 
 
Surprisingly, Hsp104A503S suppressed the toxicity of the overwhelming majority of 
dosage-sensitive genes (97.5%), whereas Hsp104 overexpression was almost 
completely ineffective (Fig. 6). In the heat map, red is used to represent toxicity of the 
overexpressed gene and blue is the suppression of toxicity (“Rescue”) of each gene by 
Hsp104A503S, which is the difference in toxicity from the BYA strain compared to BYV. 
Only genes with an average toxicity score of 0.75 or greater are shown on this heatmap 
(120 of 198 screened) and they are sorted by “Rescue” (with the greatest Hsp104A503S 
suppression of toxicity listed first to those with Hsp104A503S enhancement of toxicity listed 
last). There were only three genes of the 120 toxic genes (2.5%) that were not rescued 
by Hsp104A503S (Fig. 6). KAR1 toxicity was not suppressed by Hsp104A503S, whereas 
MUK1 and TRM5 toxicity was slightly enhanced by Hsp104A503S (Fig. 6). By contrast, the 
vast majority of toxic genes (117 of 120 or 97.5%) are suppressed by Hsp104A503S (Fig. 
6). Indeed, 95% (114 of 120) of cases of dosage sensitivity were rescued by Hsp104A503S 
by a score of 0.5 or more and 72.5% (87 of 120) were rescued by a score of 1.0 or more 
(Fig. 6). The difference in toxicity is just as stark on the spotting assay plates from which 
the quantification was obtained. The expression of the 30 most suppressed toxic genes, 
such as AKL1 and SFI1, results in virtually no growth in BYV or BYW but featured nearly 
full growth in BYA (Fig. 7). Even in examples where toxicity is more moderate like the 
top half of the second column of spottings in Fig. 7, the suppression of toxicity by 
Hsp104A503S is glaring and unmistakably obvious. To the best of our knowledge, 
Hsp104A503S is the first agent discovered to rescue such a large proportion of dosage-
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sensitive yeast genes. 
 
 
 
Figure 6: Hsp104A503S suppresses the toxicity of most dosage-sensitive yeast 
genes. 
Heat map depicting the toxicity of each dosage-sensitive gene in each strain ranked by 
Hsp104A503S suppression of toxicity from greatest to least. Human neurodegenerative 
disease gene toxicity is shown at the end of the chart. Red indicates increased toxicity, 
blue indicates increased rescue by Hsp104A503S, yellow indicates increased toxicity 
enhancement (n = 3-5 independent transformations) 
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Figure 7: Hsp104A503S but not Hsp104 suppresses the toxicity of most dosage-
sensitive yeast genes.  
Representative spotting assays from all toxic genes, sorted by suppression of toxicity by 
Hsp104A503S from most to least rescue. Heat maps from Fig. 1C were aligned to the 
corresponding spotting. 
 
To further emphasize the difference between Hsp104 and Hsp104A503S 
suppression of overexpression toxicity, the toxicity score of each gene in the BYW and 
BYA strains were compared to the control BYV in a scatter plot. The toxicity score of 
each gene in the vector control strain was plotted on the x-axis with the toxicity score of 
the gene in BYW (Fig. 8A) or BYA (Fig. 8B) on the y-axis. The best-fit linear regression 
of the data for the BYW-BYV comparison has a slope of 0.9290 ± 0.0243, with a 
coefficient of determination (r2) value of 0.9251 (Fig. 8A). This very strong positive 
correlation (where the slope and r2 values are each very close to 1) indicates that 
Hsp104 had an almost no effect on suppressing dosage sensitivity (Fig. 8A). Only a few 
genes, TPK2, SHE1, KIP3, GIP4, and HSF1, showed a difference in toxicity score of one 
or more between the BYV and BYW strains (Fig. 8A). Hsp104 weakly rescued the 
toxicity of HSF1, but enhanced toxicity of TPK2, SHE1, KIP3, and GIP4 (Fig. 6, 7, 8A). In 
sharp contrast, Hsp104A503S suppressed the toxicity of almost all toxic genes, which is 
immediately evident in the scatter plot, with most data points featuring a y-coordinate 
value (Fig. 8B). The best-fit linear regression of the data for the BYA-BYV had a slope of 
0.1980 ± 0.0393 and r2 value of 0.1769 (Fig. 8B). The flat slope of the linear regression 
fit and very low r2 value indicates that gene toxicity in BYV did not correlate with gene 
toxicity in BYA and that overall despite increasing toxicity of some genes in the BYV 
strains, Hsp104A503S overexpression was able to suppress toxicity greatly (Fig. 8B). The 
vast majority of toxic genes were suppressed in BYA (Fig. 6, 7, 8B). Only KAR1, ITT1, 
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MKS1, and GAT3 exhibited toxicity greater than 2 in BYA (Fig. 6, 7, 8B). For these 
genes, only KAR1 toxicity was unaffected by Hsp104A503S, whereas Hsp104A503S slightly 
reduced ITT1 toxicity and moderately reduced toxicty of MKS1 and GAT3 (Fig. 6, 7, 8B). 
MUK1 and TRM5 were the only two genes in which toxicity was slighly enhanced by 
Hsp104A503S (Fig. 6, 7, 8B). We also tested the ability of another potentiated Hsp104 
variant, Hsp104A503V (207), to rescue all dosage-sensitive yeast genes. Remarkably, the 
results were very a similar to Hsp104A503S, and Hsp104A503V suppressed toxicity of nearly 
all dosage-sensitive yeast genes (data not shown). Thus, Hsp104A503X mutants (except 
Hsp104A503P) might all be hyperactivated in a very similar manner and be broad-
spectrum inhibitors of overexpression toxicity in yeast.  
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Figure 8. Overexpression of Hsp104A503S but not Hsp104, Ssa1, or Hsp82 
suppresses dosage sensitivity.  
Scatter plot of toxicity of dosage-sensitive genes in yeast expressing Hsp104 (A), 
Hsp104A503S (B), Ssa1 (C), and Hsp82 (D) on the y-axis compared the vector control on 
the x-axis. The best-fit linear regression line is plotted in black.  
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2.2.2 Ssa1 and Hsp82 Overexpression Do Not Suppress Dosage Sensitivity  
To determine the specificity of Hsp104A503S dosage suppression, we also 
generated Δhsp104 yeast strains overexpressing either SSA1 (BYS) or HSP82 (BYH) 
(Fig. 9A, B). Ssa1 is a yeast Hsp70-family chaperone that is crucial for assisting folding 
of newly translated protein, preventing misfolding, shuttling aberrantly folded proteins for 
degradation, and ensuring proper protein transport to its final destination (226, 227). In 
addition, Ssa1 also collaborates with Hsp104 to disassemble protein aggregates and 
regulate yeast prions (32, 33, 228, 229). In the absence of Hsp104, Ssa1 combines with 
Sse1 (Hsp110) and Sis1 (Hsp40) to disaggregate various aggregated structures (35, 
230). Despite high cytosolic concentrations of Ssa1 and other Hsp70-class proteins in 
yeast, Ssa1 expression is greatly induced following heat or environmental stress 
suggesting that it is crucially needed under crisis conditions (231, 232). Yet, despite the 
importance of Ssa1 in maintaining proteostasis, we found that Ssa1, much like Hsp104, 
did not suppress the toxicity of most dosage-sensitive genes (Fig. 8C). There were a few 
exceptions. For example, Ssa1 potently suppressed toxicity of SQS1, REB1, YDR306C, 
ESL2, and HSF1 more than Hsp104 and slightly enhanced TDA9 toxicity (Fig. 8C). In 
general, most cases of overexpression toxicity were unaffected by Ssa1 overexpression 
where the best-fit linear regression for the BYS-BYV data has a slope of 0.9588 ± 
0.0290, with a coefficient of determination (r2) value of 0.9034 (Fig. 8C). 
We also tested Hsp82 for its ability to suppress dosage sensitivity. Hsp82 was an 
appealing candidate to test as a potential regulator of dosage sensitivity because it is an 
Hsp90-class chaperone that assists in the folding of metastable substrates that have 
difficulty achieving their final stable conformations (233). Typically, Hsp90-chaperones 
assist in protein maturation, acting only on proteins that have nearly reached their final 
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form (234). It also has a vital responsibility in folding aggregation-prone substrates and 
refolding stress or chemically-denatured proteins back to their native state (233, 235). 
Moreover, Hsp82 is critical for the correct folding of many regulatory and signaling 
proteins like kinases and TFs, many of which are dosage-sensitive (236-238). We 
expected Hsp82 to aid in the folding of some substrates to the native, active form 
potentially increasing the toxicity of some proteins while preventing misfolding of other 
proteins and suppressing their toxicity. However, when Hsp82 was overexpressed with 
the genes in the dosage-sensitive library, it did not affect the dosage sensitivity of many 
genes (Fig. 8D). Compared to the vector control, Hsp82 slightly enhanced the toxicity of 
RPH1, PDS1, GIP4, SWH1, AZF1, and SLK19 while subtly suppressing the toxicity of 
NUP100, SKN7, and ESL2 (Fig. 8D). Overall, however, the best-fit linear regression of 
the data for the BYH-BYV comparison has a slope of 0.9766 ± 0.0260, with a coefficient 
of determination (r2) value of 0.9260, which demonstrates almost no meaningful 
difference between toxicity of genes in the vector control compared to yeast 
overexpressing Hsp82 (Fig. 8A). 
These results support that Hsp104A503S has a unique activity in broad-scale 
suppression of dosage sensitivity that is not easily replicated by overexpression of other 
chaperones. Thus, neither Hsp104, Ssa1, nor Hsp82 rescued more than a handful of 
dosage-sensitive yeast genes. By engineering Hsp104 to enhance protein-remodeling 
activity via introduction of the A503S mutation in the middle domain, we have generated 
a powerful buffer able to counter the toxicity of diverse and numerous dosage-sensitive 
genes. 
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Figure 9. Ssa1 and Hsp82 are induced in yeast.  
Ssa1 (A) and Hsp82 (B) were significantly induced following transformation of a plasmid 
carrying pAG413Gal-Ssa1 and pAG413Gal-Hsp82 in BY4741Δhsp104. Part B, shows 3 
independent transformations and inductions. 
 
2.2.3 Characteristics of Dosage-sensitive Genes 
The dosage-sensitive genes that were suppressed by Hsp104A503S shared many 
features with previously described dosage-sensitive genes and fell into several general 
functional categories that are commonly enriched in dosage-sensitive genes (239): TFs, 
cytoskeleton, cell cycle/mitosis regulators, kinases, or phosphatases (Fig. 10A). GO 
(gene ontology) Term analysis for “Function” terms were primarily enriched for TF-
associated terms related to DNA binding or interactions with RNA Polymerase II 
complex (Fig. 10B). GO Term analysis for “Component” terms returned mostly 
cytoskeletal and cell cycle-related terms (Fig. 10B). Bioinformatic analysis of the dosage-
sensitive genes revealed that 7 of 10 most enriched terms were for protein unfoldedness 
(Fig. 11A), consistent with other studies of dosage-lethality (4). Dosage-sensitive 
proteins are also highly enriched in linear sequence motifs (4). These linear motifs are 
short protein sequences that can be recognized by common signaling domains, 
phosphorylated by Serine/Threonine- or Tyrosine-kinases or mediate binding 
interactions with protein or phospholipids (240). The enrichment of linear sequence 
 42 
 
motifs in dosage-sensitive proteins provides support for the interaction promiscuity 
hypothesis for dosage sensitivity, which posits that these exposed linear motifs may 
provide additional modalities for aberrant interactions (4). 
47 of the 120 dosage-sensitive yeast genes were determined to have human 
homologs by sequence homology (Table 2). Of these, 10 yeast genes, HRD1, FKH1, 
FHL1, HSF1, KIP1, KIP3, PBS2, SMP1, TUB2, and RSP5, have human homologs with 
OMIM (Online Mendelian Inheritance in Man) annotated disease associations, which are 
varied including renal cell carcinoma, mental retardation, and anemia (Table 2). 
Of the 120 toxic genes, the localization of 91 proteins was reported in a global 
analysis of localization in yeast where each gene was C-terminally GFP tagged in its 
original chromosomal location (241). The localization profile of the dosage-sensitive 
proteins was similar to those of all proteins in general (Fig. 11B), with about half of the 
toxic proteins (45 of 91, 49.5%) reported as localized to the cytoplasm compared to 
studies that estimated 47% all proteins to be cytoplasmic in proteome-wide studies 
(242). However, there are some differences from reported subcellular 
compartmentalization of yeast proteins. The biggest outlier is the enrichment of nuclear 
proteins in the dosage-sensitive set, 43 of 91 (47.3%) annotated genes (Fig. 11B), which 
is greater than the 27% reported for the entire yeast proteome (242). In large part, this is 
due to overrepresentation of transcription factors in the dosage-sensitive gene library, 
with accounted for nearly 20% (21 of 120) of toxic genes in the library we created (Fig. 
10A). In contrast, genes in the mitochrondia and exocytic networks (ER, Golgi, and 
secretory pathways), reported to be approximately 13% of the proteome each 
respectively (242), were underrepresented in our dosage-sensitive gene set (Fig.11B). 
The large proportion of genes that are localized to the cytoplasm, nucleus, or both and 
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relatively few number of genes localized to membrane isolated organelles allows 
Hsp104A503S to easily engage these substrates. 
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Figure 10. Features of dosage-sensitive genes suppressed by Hsp104A503S.  
A. Toxic genes with toxicity as shown in Fig. 1C grouped by function. B. The Gene 
Ontology Term Finder reveals significant enrichment of genes with DNA-
binding/Transcription Factor associated “Function” terms and cytoskeletal or nuclear 
“Component” terms.  
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Figure 11. Dosage-sensitive proteins are enriched for predicted disorder or 
unfoldedness and generally localized to the nucleus or cytoplasm.  
A. Dosage-sensitive gene set was compared to the rest of the genome for features that 
were correlated with dosage sensitivity. A cross-validation experiment was used to 
determine the predictiveness of each feature for gene dosage sensitivity. The mean area 
under a receiver operating characteristic (ROC) curve for each of the cross-validation 
experiments was plotted for each feature. 7 of the top 10 most correlated terms are 
associated with predicted intrinsic protein disorder (IUcount, ANCHORcount, FInumaa, 
Intrinsic.Disorder.GlobPlot, IUmaxrun, Intrinsic.Disorder, DisEMBL.COILS, FImaxrun), 
the others refer to protein length, enrichment for linear motifs (ELMcount), and high 
Asparagine content. Analysis performed by Oliver King. B. Each dosage-sensitive gene 
with a reported localization (91 of 120) from a global study was counted and the 
distribution by localization terms are given (241). The localization categories are not 
mutually exclusive with over 30 assigned two or more localization including 16 that were 
reported as having both cytoplasmic and nuclear localization. 
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Yeast 
Gene 
Yeast 
Systematic Human Homolog 
Human Diseases Associated 
with Gene 
ARK1 YNL020C AAK1, BMP2K   
AKL1 YBR059C AAK1, BMP2K   
RNH70 YGR276C 
AC004381.6, REXO1, 
REXO1L11P, REXO1L1P, 
REXO1L10P 
  
HRD1 YOL013C AMFR, SYVN1, RNF145, RNF139 Renal Cell Carcinoma (RNF139) 
NAM8 YHR086W C6orf52, TRNAU1AP   
CLB6 YGR109C CCNB1, CCNB2, CCNE2, CCNE1, CCNB3   
CLB3 YDL155W CCNB1, CCNB2, CCNE2, CCNE1, CCNB3   
CLB2 YPR119W CCNB1, CCNB2, CCNE2, CCNE1, CCNB3   
CLB5 YPR120C CCNB1, CCNB2, CCNE2, CCNE1, CCNB3   
CDH1 YGL003C CDC20B, CDC20, FZR1   
CHD1 YER164W CHD5, CHD4, CHD3, CHD1, CHD2   
SUI3 YPL237W EIF2S2   
FKH1 YIL131C FOXJ1, FOXK1, FOXK2 Allergic Rhinitis (FOXJ1) 
FHL1 YPR104C FOXN1, FOXN4, FOXH1 Immunodeficiency, Congenital Alopecia, and Nail Dystrphy (FOXN1) 
HSF1 YGL073W HSF1, HSF2, HSF4 Cataracts (HSF4) 
INM1 YHR046C IMPA1, IMPA2   
SXM1 YDR395W IPO7, IPO8   
NMD5 YJR132W IPO7, IPO8   
RPH1 YER169W KDM4B, KDM4C, KDM4D, KDM4E, KDM4A   
GIS1 YDR096W KDM4B, KDM4C, KDM4D, KDM4E, KDM4A   
KIP1 YBL063W KIF11 Microcephaly 
KIP3 YGL216W KIF19, KIF18B, KIF18A, KIF22 Spondyloepimetaphyseal Dysplasia with Joint Laxity Type 2 (KIF22) 
KAP95 YLR347C KPNB1   
MDM38 YOL027C LETM2, LETM1   
PBS2 YJL128C MAP2K7, MAP2K1, MAP2K2, MAP2K5 
Cardiofaciocutaneous Syndrome 3 
(MAP2K1); Cardiofaciocutaneous 
Syndrome 4 (MAP2K2) 
SSK2 YNR031C MAP3K4   
SMP1 YBR182C MEF2C, MEF2A, MEF2BNB-MEF2B, MEF2B, MEF2D 
Mental Retardation (MEF2C); 
Coronary Heart Disease (MEF2A) 
SWH1 YAR042W OSBPL2, OSBPL1A, OSBP2, OSBP   
NFI1 YOR156C PIAS1, PIAS3, ZMIZ2, PIAS2, ZMIZ1, PIAS4   
GLC7 YER133W PPP1CC, PPP1CB, PPP1CA   
TPK2 YPL203W PRKX, PRKG2, PRKACB, PRKACA, PRKG1, PRKACG   
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TPK3 YKL166C PRKX, PRKG2, PRKACB, PRKACA, PRKG1, PRKACG   
ITT1 YML068W RNF14   
SAC3 YDR159W SAC3D1, MCM3AP   
SEC31 YDL195W SEC31B, SEC31A   
ULP2 YIL031W SENP6, SENP7   
SED5 YLR026C STX5   
SPT5 YML010W SUPT5H   
TOP1 YOL006C TOP1MT, TOP1   
TRM11 YOL124C TRMT11   
TRM5 YHR070W TRMT5   
TUB2 YFL037W TUBB8, RP11-683L23.1, TUBB2B, TUBB1, TUBB2A 
Polymicrogyria (TUBB2B); 
Macrothrombocytopenia (TUBB1) 
STE4 YOR212W WDR47, GNB5   
RSP5 YER125W WWP2, ITCH, NEDD4L, NEDD4, WWP1 
Syndromic Multisystem Autoimmune 
Disease (ITCH) 
MSN5 YDR335W XPO5   
CTH1 YDR151C ZFP36, ZFP36L1, ZFP36L2   
TIS11 YLR136C ZFP36, ZFP36L1, ZFP36L2   
 
Table 2: Dosage-sensitive yeast genes with human homologs and disease 
associations 
Dosage-sensitive yeast genes are listed with human homologs. Human homologs with 
OMIM (Online Mendelian Inheritance in Man) annotated disease associations are given. 
Human genes associated with the specific disorder are shown in bold if more than one 
homolog exists for a yeast gene. Analysis performed by Oliver King. 
 
2.2.4 Hsp104A503S Does Not Typically Rescue Dosage Sensitivity by Reducing 
Protein Expression 
One possible explanation for the broad-spectrum rescue of overexpression 
toxicity was that Hsp104A503S simply reduced toxic protein expression. However, 
previous studies established that Hsp104A503S rescues TDP-43 and α-synuclein toxicity 
without affecting their expression level in yeast (207-210). Indeed, we confirmed that 
Hsp104A503S rescued TDP-43 and α-synuclein toxicity without affecting their expression 
level (Fig. 12A, B). However, we did observe a modest reduction in FUS expression by 
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Hsp104A503S, which had also been observed previously (208). Thus, Hsp104A503S can 
rescue toxicity of human neurodegenerative disease proteins without affecting their 
expression, but would the same be true for the yeast dosage-sensitive proteins? 
We analyzed the expression levels of 18 dosage-sensitive yeast proteins to 
determine if Hsp104A503S was lowering toxic protein expression. Utilizing Gateway 
cloning technology, dosage-lethal genes were inserted into a modified pAG413Gal-ccdb 
destination vector with an N-terminal 6x hemagglutinin (HA) tag upstream of the gateway 
cloning sequence. The HA-fusions were transformed into and expressed in BYV, BYW, 
and BYA strains. 18 HA-fusions that produced growth phenotypes similar to that of 
untagged protein were chosen for quantitative Western Blot analysis (Fig. 12A). 
Although, curiously, addition of the HA tag to Glc7 enabled Hsp104 to rescue toxicity in 
addition to Hsp104A503S (Fig. 12A). Triose-phosphate dehydrogenase, Tdh1, is not toxic 
when overexpressed and was used as a control in the analysis (Fig. 12A). Hsp104A503S 
coexpression with Tdh1 resulted in a slight (~12%), but not statistically significant, 
decrease in protein expression (Fig. 12B). Of the dosage-sensitive proteins, 4 of 18 
(Glc7, Bni4, Tbf1, and Fkh1) showed no decrease in expression in BYA compared to 
BYV or BYW, indicating that Hsp104A503S can rescue toxicity without affecting toxic 
protein expression level as with TDP-43 and α-synuclein (Fig. 12B) (207, 209, 210). 12 
of 18 (Ppz1, Bik1, Hsf1, Kap95, Gip3, Skn7, Nam8, Ark1, Clb3, Swh1, Nab3, and Hms1) 
dosage-sensitive proteins showed a slight to modest decrease in expression level (~12-
36%) in the BYA strain compared to the BYV control, but none of these differences were 
statistically significant (Fig. 12B). Moreover, Hsp104 slightly to modestly reduced protein 
expression level (by ~7-34%) to a similar extent as Hsp104A503S for five of these dosage-
sensitive proteins (Ppz1, Bik1, Kap95, Skn7, and Ark1), but conferred no rescue of 
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toxicity (Fig. 12A, B). Therefore, slight to modest reduction of protein expression level is 
not sufficient to rescue toxicity in these cases. However, Hsp104A503S significantly 
decreased expression of Akl1 (~60%) and Slk19 (~62%) compared to the vector and 
Hsp104 controls (Fig. 12B). Thus, reduced protein levels of Akl1 and Slk19 by 
Hsp104A503S could contribute to the reduction in toxicity. Furthermore, when the 
decreases in expression of each gene was plotted against the suppression of toxicity by 
Hsp104A503S, there was no correlation between the two variables (r2 = 0.0329), indicating 
that decreased protein expression does not provide a general explanation for rescue of 
toxicity by Hsp104A503S (Fig. 13). These studies indicate that typically Hsp104A503S does 
not rescue overexpression toxicity by reducing protein expression. 
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Figure 12. Hsp104A503S expression reduces the expression of some dosage-
sensitive genes.  
A. N-terminal 6xHA tagged dosage-sensitive genes were transformed in yeast carrying 
an empty vector or galactose-inducible Hsp104 or Hsp104A503S. The toxicity of untagged 
dosage-sensitive proteins (left) was similar to HA-tagged (right) B. Expression levels of 
HA-tagged dosage-sensitive proteins and human neurodegenerative disease-associated 
proteins, α-Synuclein, TDP-43, and FUS were measured by Western blot analysis. α-
Synuclein was C-terminally tagged with 6x-HA, TDP-43 and FUS were untagged and 
detected with antibody to endogenous epitope. Representative blots for the loading 
control, Pgk1, and tagged protein, HA, are shown to the left. Quantification of the 
Western blots are given to the right. HA-tagged protein expression normalized to the 
vector control strain. Blue indicates decrease in expression, red indicates increase in 
expression. (Mean ± s.e.m., n = 3-5 independent transformations, Two-way ANOVA 
using Fisher’s LSD Test, * P< 0.05, ** P<0.01, black * only statistically significant 
difference between BYV-BYA, red * statistically significant difference between BYV-BYA 
and BYW-BYA). 
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Figure 13. Hsp104A503S reduction of protein levels not correlated with suppression 
of toxicity.  
Scatter plot of HA-tagged protein toxicity suppression by Hsp104A503S expression versus 
HA-tagged protein expression levels in the Hsp104A503S strain. The best-fit linear 
regression is plotted in black. 
 
2.2.5 Dosage-sensitive Proteins Do Not Form Amyloids in Yeast 
A primary function of Hsp104 in yeast is to disaggregate proteins that accumulate 
in amyloid structures and disordered aggregates (32, 172, 180, 243, 244). Thus, we 
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assessed whether HA-tagged toxic proteins formed SDS-resistant amyloid structures, 
and if Hsp104 or Hsp104A503S prevented their assembly. 4 of the 18 proteins tested 
(Akl1, Hms1, Nab3, and Nam8) were among the top 179 candidates in a study that 
identified yeast proteins with putative prion domains, a type of intrinsically disordered, 
low-complexity domain enriched in glutamine, asparagine, tyrosine, and glycine residues 
(245). However, none of these candidates formed bona fide prions in yeast (245). Using 
semi-denaturing detergent agarose gel electrophoresis (SDD-AGE) analysis with the 
standard 2.0% SDS (Fig. 14) and lowered, less stringent 0.5% SDS (data not shown), 
we did not detect the presence of high-molecular weight smears indicative of amyloid in 
lysates from BYV, BYW, and BYA yeast expressing the dosage-sensitive proteins (Fig. 
14). For Akl1, Hms1, Nab3, and Nam8 these findings were consistent with a previous 
study, which also found these proteins did not assemble into SDS-resistant structures 
detected by SDD-AGE (245). By contrast, the yeast prion protein, Rnq1, readily formed 
these structures in wild-type yeast (Fig. 14). These results were not unexpected in the 
vector control, which lacks endogenous Hsp104 that is essential in the formation and 
maintenance of amyloid-based prion states in yeast (180). However, these findings 
confirm that these proteins are not forming toxic amyloid conformers in yeast. Likewise, 
the human neurodegenerative disease-associated proteins also did not require the 
formation of amyloid to be toxic (Fig. 14). Thus, Hsp104A503S does not need to utilize its 
amyloid-disaggregase activity to suppress the deleterious growth defect caused by 
dosage-sensitive yeast genes, TDP-43, FUS, or α-synuclein. 
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Figure 14. HA-tagged dosage-sensitive proteins do not form large, SDS-resistant 
aggregates or amyloid.  
Representative SDD-AGE of HA-tagged dosage-sensitive proteins expressed in yeast 
with vector control (V), Hsp104 (W), and Hsp104A503S (A). The lack of a distinct high 
molecular weight smears show that these proteins do not form SDS-resistant, 
aggregated species consistent with amyloid formation. Rnq1-YFP readily formed SDS-
resistant, high molecular weight species in wild-type BY4741 yeast with Hsp104 (+), but 
not in a BY4741 Δhsp104 strain (-) in which Hsp104 is disrupted. 
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2.2.6 Hsp104A503S Coexpression Abrogates Aggregate Formation 
Next, we assessed whether Hsp104A503S might prevent the formation of a less 
stable, aggregated protein species to counter toxicity. Thus, we developed a filter 
retention assays with milder conditions (0.1% SDS and 0.1% Triton X-100) than used for 
SDD-AGE to determine if detergent-labile, less stable aggregates were formed in BYV 
that were prevented or dissolved in BYA with Hsp104A503S expression. We used a 
vacuum-based dot blot apparatus to apply the lysates to two consecutively stacked 
membranes; first, a 0.2µm cellulose acetate (CA) membrane that trapped large 
aggregates but allowed structures smaller than the pore size to pass through and bind to 
the second nitrocellulose (NC) membrane underneath (Fig. 15).  
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Figure 15. Filter Retention Assay.  
The Filter retention assay was used to isolate, large aggregates formed in yeast. Lysates 
from BYV, BYW, and BYA yeast expressing HA-tagged proteins were applied to two 
stacked membranes: first, the 0.2µm cellulose acetate (CA) filter that traps large 
aggregates but allows soluble proteins to pass through to the nitrocellulose (NC) 
membrane. 
 
We observed detectable aggregate formation (i.e. retention by the CA 
membrane) by all dosage-sensitive toxic proteins in the BYV background (Fig. 16A, B). 
Increasing the concentration of SDS to 2% with or without boiling the lysates resulted in 
almost complete dissolution of aggregate species on the CA membrane (Fig. 17A, B). 
Thus, in general these protein aggregates were not very stable and were detergent 
soluble, indicating they are more likely to be more labile, disordered aggregates. The 
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only exceptions were Glc7, Bik1, Kap95, Nam8, and Gip3, which appeared to form some 
aggregated structures that were SDS-resistant at room temperature (Fig. 17B). 
Importantly, non-toxic proteins, Adh1, Amd1, and Tdh1 did not form aggregated 
structures detected by this assay (Fig. 17C, D). Interestingly, Kar1, a dosage-sensitive 
protein whose toxicity is not suppressed by Hsp104 or Hsp104A503S does not form 
significant amounts of aggregated protein. However, in general, the presence of these 
aggregated structures correlates with toxicity. Indeed, the toxic human 
neurodegenerative disease proteins, TDP-43, FUS, and α-synuclein also formed 
aggregated structures in the BYV background that were trapped by the CA membrane 
(Fig. 16A, B). 
Consistent with previous studies (207, 208), Hsp104 did not affect the 
aggregation of TDP-43, FUS, and α-synuclein (Fig. 16A, B), and is unable to rescue 
their toxicity (Fig. 5C). Likewise, Hsp104 did not significantly reduce the amount of 
aggregated HA-tagged Glc7, Ppz1, Kap95, Gip3, Skn7, Bni4, Tbf1, Ark1, Fkh1, Clb3, 
Akl1, Swh1, Kip1, Nab3, 14 of the 18 dosage-sensitive yeast proteins tested (Fig. 16A, 
B). Hsp104 is also unable to rescue the toxicity of these proteins except for HA-tagged 
Glc7 (Fig. 12A). Thus, the rescue of HA-tagged Glc7 toxicity by Hsp104 is likely not 
related to alterations in Glc7 aggregation. Interestingly, Hsp104 significantly reduced the 
aggregation of HA-tagged Bik1, Hsf1, Nam8, and Slk19 (Fig. 16A, B), but did not 
suppress their toxicity (Fig. 12A). Thus, preventing aggregation to this extent alone 
appears insufficient to eliminate toxicity for these proteins.  
Consistent with previous studies (207, 208), Hsp104A503S prevented aggregation 
of TDP-43, FUS, and α-synuclein (Fig. 16A, B), and rescued their toxicity (Fig. 12C). 
Strikingly, Hsp104A503S also significantly reduced aggregate formation by 14 of 18 
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dosage-sensitive proteins (Ppz1, Bik1, Hsf1, Gip3, Skn7, Tbf1, Nam8, Ark1, Fkh1, Clb3, 
Swh1, Kip1, Nab3, and Slk19) compared to the vector control (Fig. 16A, B). It also 
reduced aggregate formation by Glc7, Kap95, Bni4, and Akl1 (Fig. 16A, B), but here the 
difference compared to the vector control was not statistically significant, although the 
reduction in aggregates for Glc7 and Bni4 was significant compared to Hsp104 (Fig. 
16A, B). Hsp104A503S rescued the toxicity of all of these HA-tagged proteins (Fig. 12A). 
However, Hsp104A503S was unable to prevent the toxicity of HA-tagged Kar1 (Fig. 17C, 
D), a highly toxic protein(246). Thus, aggregate dissolution may generally be utilized by 
Hsp104A503S to suppress protein toxicity. Collectively, these findings indicate that rescue 
of overexpression toxicity by Hsp104A503S is typically accompanied by a reduction in the 
amount of toxic protein entering SDS-soluble aggregates. 
With 6 of the 18 HA-tagged proteins, Glc7, Ppz1, Bni4, Fkh1, Clb3, and Kip1, 
Hsp104A503S reduced aggregate formation significantly more compared to Hsp104 (Fig. 
16A), confirming its enhanced activity compared to Hsp104. In all cases tested and 
quantified, Hsp104A503S reduced aggregate formation more effectively than Hsp104 (Fig. 
16A, B). Moreover, Hsp104 significantly reduced the aggregation of HA-tagged Bik1, 
Hsf1, Nam8, and Slk19 (Fig. 16A, B), but did not rescue their toxicity (Fig. 8A). These 
findings suggest that the mechanism by which Hsp104A503S prevents protein aggregation 
to rescue toxicity is different from Hsp104, which can also impede the aggregation of 
some toxic proteins but without alleviating toxicity (Fig. 12A, 16A, B). Thus, Hsp104A503S 
may prevent the formation of particularly toxic aggregated structures, whereas Hsp104 
only prevents the formation of benign aggregated structures and not toxic species. That 
is, aggregates formed in the presence of Hsp104 possess a different toxic structure (or 
‘strain’), whereas those formed in the presence of Hsp104A503S do not. The ability of 
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Hsp104 to promote different ‘strains’ of protein aggregates with different phenotypic 
properties (e.g. toxicity) has been observed previously in the context of Sup35 prions 
(247) and polyglutamine aggregation (217). Alternatively, Hsp104A503S may also prevent 
the co-aggregation of other proteins that contributes to toxicity, whereas Hsp104 may 
not. Thus, aggregates formed in the presence of Hsp104 may sequester other essential 
proteins and continue to confer toxicity. Further experiments are required to distinguish 
between these possibilities.  
Finally, it is also possible that Hsp104A503S exerts additional effects on soluble 
forms of toxic proteins, which are not exerted by Hsp104. For example, Hsp104A503S may 
disassemble toxic soluble oligomers, whereas Hsp104 may not. Alternatively, 
Hsp104A503S may preferentially recognize the unfolded stretches of toxic proteins and 
unfold, remodel, or otherwise inactivate the entire toxic protein, whereas Hsp104 may 
not. Previous studies suggest that Hsp104A503V recognizes shorter unfolded segments of 
proteins than Hsp104, and also promotes their rapid unfolding and inactivation in 
situations where Hsp104 has no effect (207, 208). Thus, we anticipate that in addition to 
preventing toxic aggregation, Hsp104A503S also has a direct effect on soluble forms of the 
toxic protein, which contributes to rescue of toxicity. 
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Figure 16: Hsp104A503S prevents aggregation of dosage-sensitive proteins.  
A. The bar graph shows the quantification of aggregated protein detected by filter 
retention assay as a ratio of aggregated (bound to the cellulose acetate) to flowthrough 
soluble protein (bound to nitrocellulose). The values for the Hsp104 and Hsp104A503S 
expressing strains were normalized to the vector control strain (Mean ± s.e.m., n = 3-5 
independent transformations, Two-way ANOVA using a Fisher’s LSD Test, * P< 0.05, ** 
P<0.01, *** P < 0.0001, black * indicates statistical difference compared to BYV, red * 
indicates statistical difference between BYV-BYA and BYW-BYA with number of * only 
for BYV-BYA comparisons, P < 0.05 for all BYW-BYA comparisons, blue * indicates 
statistical differences between BYW-BYA comparisons only). B. Representative filter 
retention blots showing the aggregation state of HA-tagged proteins bound to the 
cellulose acetate (CA) and nitrocellulose (NC) membranes in the vector control, Hsp104, 
and Hsp104A503S strains. 
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Figure 17. High concentrations of SDS or boiling dissolve aggregates of dosage-
sensitive proteins.  
A. Representative filter assay using lysates boiled in sample buffer with 2% SDS at 99°C 
for 5 minutes. B. Representative filter retention assay with lysates treated with 2% SDS 
sample and incubated at 20°C for 5 minutes. C. Filter retention assay with non-dosage-
sensitive proteins (Adh1, Amd1, and Tdh1), which do not form aggregates in BYV, BYW, 
or BYA strains. The non-suppressed dosage-sensitive protein, Kar1, also does not form 
in BYV, BYW, or BYA strains. D. Spotting assays of BYV, BYW, and BYA yeast 
expressing HA-tagged Adh1, Amd1, Tdh1, and Kar1.  
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2.2.7 Defining Substrate Binding and ATPase Modalities Needed For Hsp104A503S 
to Suppress Overexpression Toxicity. 
To elucidate the mechanistic requirements for suppression of overexpression-
induced toxicity, we introduced several deactivating mutations to Hsp104A503S, targeting 
the residues of Hsp104A503S critical for effective substrate binding and remodeling, as 
well as ATP hydrolysis (Fig. 18A). Alanine substitutions to each of the two pore loops 
tyrosines, Y257 (in NBD1) and Y662 (in NBD2), severely dampen substrate binding at 
each pore loop and translocation through the central pore of Hsp104 (174, 248, 249). 
Glutamine substitutions to each of the two Walker B motif glutamates, E285 (in NBD1) 
and E687 (in NBD2), abolishes ATP hydrolysis but not binding, allowing the formation of 
hexamers that can engage and bind substrate but not disassemble them (250). Thus, we 
constructed seven Hsp104A503S variants to define substrate-binding and ATPase 
modalities necessary to rescue overexpression toxicity: Hsp104Y257A:A503S (termed PL1, 
‘pore loop NBD1’, which is dysfunctional in substrate binding to the NBD1 pore loop), 
Hsp104A503S:Y662A (termed PL2, ‘pore loop NBD2’, which is dysfunctional in substrate 
binding to the NBD2 pore loop), Hsp104Y257A:A503S:Y662A (termed DPL, ‘double pore loop’, 
which is dysfunctional in substrate binding to the NBD1 and NBD2 pore loops), 
Hsp104E285Q:A503S (termed WB1, ‘Walker B motif NBD1’, which is dysfunctional in ATP 
hydrolysis at NBD1), Hsp104A503S:E687Q (termed WB2, ‘Walker B motif NBD2’, which is 
dysfunctional in ATP hydrolysis at NBD2), Hsp104E285Q:A503S:E687Q (termed DWB, ‘Double 
Walker B’, which is dysfunctional in ATP hydrolysis at NBD1 and NBD2), and 
Hsp104Y257A:E285Q:A503S:Y662A:E687Q (termed DPL DWB, ‘Double Pore Loop Double Walker 
B’, which is dysfunctional in substrate binding and ATP hydrolysis at NBD1 and NBD2). 
These pore loop and ATPase Hsp104A503S variants were robustly expressed in Δhsp104 
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yeast (Fig. 18B). These Hsp104A503S variants were screened against the dosage-
sensitive gene library. 
 
Figure 18. Mutations of Hsp104A503S that reduce substrate binding and ATPase 
activity are well expressed.  
The Y257A and Y662A mutations inactivate the substrate-binding pore loops and the 
E285Q and E687Q Walker B mutations prevent ATP hydrolysis but not ATP binding in 
NBD1 and NBD2 respectively. A. On the structural model of Hsp104, the blue spheres 
depict the location of the substrate-binding tyrosines along the central pore and the red 
spheres the Walker B glutamates that bind ATP. B. Western blots of ∆hsp104 yeast 
expressing Hsp104A503S pore loop and Walker B mutants show robust expression of all 
seven mutants. 
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As anticipated from previous studies on Hsp104A503V (251), rescue of toxicity of 
the human neurodegenerative disease proteins, TDP-43, FUS, and α-synuclein, by 
Hsp104A503S was severely impaired in PL1, PL2, DPL, DWB, and DWBDPL (Fig. 19). 
However, WB1 and WB2 displayed partial ability to rescue (Fig. 19) (251). Thus, both 
substrate-binding pore loops are critical for rescue of TDP-43, FUS, and α-synuclein 
toxicity (251). By contrast, ATP hydrolysis at NBD1 or NBD2 is sufficient for partial 
rescue of TDP-43, FUS, and α-synuclein toxicity, but ATP hydrolysis at both NBDs is 
required for complete rescue (Fig. 19) (251). These findings suggest that the protein-
remodeling activity, protein disaggregase activity, or both are required for Hsp104A503S to 
rescue TDP-43, FUS, and α-synuclein toxicity in yeast (251). 
 For most dosage-sensitive yeast proteins, functional pore-loop tyrosine residues 
and ATP hydrolysis by both NBDs were very important for full dosage suppression 
provided by Hsp104A503S (Fig. 19). Interestingly, as with the human neurodegenerative 
disease proteins, single Walker B variants of Hsp104A503S, WB1 or WB2, were partially or 
fully active against diverse toxic proteins (Fig. 19). Thus, in many cases, ATP hydrolysis 
at NBD1 or NBD2 is sufficient to rescue overexpression toxicity. By contrast, single pore-
loop variants, PL1 or PL2, were typically more inactivating and allowed the rescue of 
relatively few toxic proteins (Fig. 19). As expected, the DPL, DWB, and DPLDWB 
variants were almost completely inactive in rescuing overexpression toxicity (Fig. 19). 
These findings suggest that the protein-remodeling activity, protein disaggregase 
activity, or both are required for Hsp104A503S to rescue the toxicity of most dosage-
sensitive genes in yeast 
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Figure 19. Pore loop and Walker B mutations greatly diminished Hsp104A503S 
suppression of dosage-sensitive gene toxicity.  
Spotting assay quantification of yeast co-expressing dosage-sensitive proteins and 
Hsp104A503S mutants: Y257A (PL1), Y662A (PL2), Y257A:Y662A (DPL), E285Q (WB1), 
E687Q (WB2), E285Q:E687Q (DWB), Y257A: E285Q: Y662A:E687Q (DPL DWB). Red 
indicates increased toxicity, blue indicates increased rescue, yellow indicates increased 
toxicity enhancement (n = 2-4 independent transformations).  
 
When each variant is directly compared to Hsp104A503S for dosage suppression, 
several notable features emerge. Alanine mutations to the individual substrate-binding 
 67 
 
tyrosines, PL1 (Y257A) and PL2 (Y662A), each almost completely abolished A503S 
potentiation of Hsp104 (Fig. 20A, B). Of the 86 toxic genes that were suppressed by 
Hsp104A503S by a score of 1 or more, only 11 of these genes were still suppressed by 
that level when Y257A was introduced: RSP5, CHD1, KAP122, SFB3, PDS1, RTG3, 
ASE1, NFI1, YDR306C, HSF1 and ECM9 (Fig. 20A, 21A, 22A). For Y662A, there are six 
genes that fit this criteria: SEC31, CHD1, KAP122, HSF1, TUB2, and HSF1; and seven 
genes for DPL: SEC31, KAP122, CHD1, PDS1, HSF1, ECM9, and YDR306C (Fig. 20B, 
21A, 22A). PDS1, KAP122, HSF1, and CHD1 were the only genes rescued by all three 
of the pore-loop variants (Fig. 20C, 21A, 22A). This strongly indicates that substrate 
binding and especially the 662-position Tyrosine is crucial for Hsp104A503S potentiation, 
and loss of substrate binding at either tyrosine effectively nearly ablates Hsp104A503S-
mediated suppression of dosage sensitivity. The few toxic proteins that were rescued by 
PL1, PL2, or DPL variants might interact with the NTD of Hsp104A503S, which is also able 
to engage substrates and plays a key role Hsp104 potentiation (189). Alternatively, the 
rescue of these toxic proteins might be mediated by an indirect effect. 
Intriguingly, single Walker B motif mutations, WB1 and WB2, were generally 
much more effective at suppressing overexpression toxicity than the pore loop variants 
(Fig. 19, 20D, E). Of the 86 toxic genes that Hsp104A503S suppressed by a score of 1 or 
more, the WB1 mutants of Hsp104A503S suppressed the toxicity of 47 genes by a score of 
1 or more and WB2 mutant suppressed 45 genes in the same manner. Surprisingly, the 
set of genes suppressed are almost completely overlapping. 43 are suppressed by both 
WB1 and WB2 (43 of 49 unique genes, 87.8%), with only BBP1, RPI1, STE4, and SUI1 
uniquely rescued by WB1 and AFT2 and PAM1 suppressed only by WB2 (Fig. 21). This 
remarkable result suggest that that certain substrates are specifically more amenable to 
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suppression by Hsp104A503S than others and that full ATPase activity is required for other 
substrates. In the case of MHP1, ARK1, NFI1, and AKL1, these very toxic genes were 
suppressed by both WB1 and WB2 nearly to the same extent as the fully ATPase-
competent version, Hsp104A503S (Fig. 22B). The DWB and DPLDWB strains show almost 
no suppression of toxic genes in comparison to Hsp104A503S (Fig. 20F, G). Here too, any 
suppression of toxicity likely stems from passive chaperone activity of the Hsp104A503S, 
which could involve the pore loops and NTD for DWB, and likely just the NTD for 
DPLDWB. The best-fit linear regression fit data from these scatter plots (Fig. 20) 
illustrate the lack of suppression of PL1, PL2, DPL, DWB, and DPLDWB in preventing 
dosage sensitivity and the relative robustness of WB1 and WB2 (Table 2). These data 
suggest that the increased effectiveness of Hsp104A503S requires substrate binding to 
both NBD pore loops and ATPase activity at both NBDs. However, Hsp104A503S activity 
is more sensitive to mutations that disrupt substrate binding at either NBD than 
mutations that disrupt ATPase activity at either NBD (251). 
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Figure 20. Pore loop mutations more significantly decrease Hsp104A503S 
potentiation than Walker B motif mutations.  
Scatter plots of the suppression of each dosage-sensitive protein in Hsp104A503S (x-axis) 
compared to suppression by each pore loop or Walker B variant in Hsp104A503S (y-axis): 
A. Hsp104Y257A,A503S (PL1); B. Hsp104A503S,Y662A (PL2); C. Hsp104Y257A,A503S,Y662A (DPL); D. 
Hsp104E285Q,A503S (WB1); E. Hsp104A503S,E687Q (WB2); F. Hsp104E285Q,A503S,E687Q (DWB); 
G. Hsp104YY257A,E285Q,A503S,Y662A,E687Q (DPL DWB). The blue line in A-G corresponds to 
y=1, i.e. suppression of toxicity of 1 in the mutant strains. 
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Figure 21. Hsp104A503S with Walker B motif mutations suppresses dosage 
sensitivity of many genes. 
A heat map depicting the genes suppressed by single Walker B motif mutants of 
Hsp104A503S (WB1 and WB2). Suppression is scored as in Figure 20 with blue indicating 
increased rescue. Black boxes are for suppression scores below 1. 
 
 
Table 3. Only single Walker B mutants of Hsp104A503S are consistent suppressors 
of diverse dosage-sensitive genes.  
The slope and coefficient of determination (r2) values based on the best-fit linear 
regressions for the scatter plots shown in Figure 16 comparing Hsp104A503S suppression 
of toxicity to each of the pore loop and Walker B motif mutants. 
 
Notably, mutations to the pore loops and Walker B motifs were not only null in 
suppressing toxicity of some dosage-sensitive genes, but actually enhanced toxicity of 
many genes (Fig. 19, 20A-G). Even with the single Walker B Hsp104A503S mutants that 
retain some rescue activity, 10-15% of genes fall below the x-axis indicating negative 
suppression scores or enhanced toxicity (Fig. 20D, E). For the PL1, PL2, DPL, DWB, 
DPL DWB Hsp104A503S mutants, the toxicity of up to 50% of genes was enhanced. Some 
genes such as CDH1 exhibited greatly enhanced toxicity when co-expressed with PL1, 
PL2, DPL, DWB, or DPLDWB, but were still rescued by WB1 or WB2 (Fig. 20A-G, 22C). 
Other genes, such as CST6 exhibited greatly enhanced toxicity when co-expressed with 
PL1, PL2, DPL, DWB, or DPLDWB, but toxicity was unaffected by WB1 or WB2 (Fig. 
20A-G, 22C). These synthetic lethal phenotypes are intriguing and may stem from 
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incomplete or partial remodeling of substrates to more toxic conformations by these 
Hsp104 variants. Alternatively, these defective Hsp104A503S variants may hinder the 
activity of molecular chaperones that would ordinarily engage these toxic substrates and 
reduce toxicity. 
 
 
Figure 22. Mutations of Hsp104 that reduce substrate binding and ATPase activity 
diminish Hsp104A503S suppression of dosage-sensitive gene toxicity.  
A. Representative serial dilution spottings show that despite mutations to pore loops the 
toxicity of PDS1 and KAP122 were still partially suppressed. B. Single Walker B mutants 
(WB1 and WB2) were still able to suppress the toxicity of 4 very toxic genes: MHP1, 
ARK1, NF1, and AKL1. C. CDH1 and CST6 over expression were slightly toxic in the 
vector, Hsp104, or Hsp104A503S strains, but in the PL1, PL2, DPL, DWB, and DPL DWB 
strains these two genes were very toxic when expressed, showing an enhancement of 
toxicity. WB1 and WB2, were able to provide partial rescue of toxicity for CDH1 and 
CST6. 
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2.2.8 Autophagy and Proteasome Activity Are Not Required for Hsp104A503S 
Activity 
Next, we sought to determine if the rescue of overexpression toxicity by 
Hsp104A503S was due to increased activity of Hsp104A503S alone or whether it also 
required downstream degradation pathways. We screened three yeast deletion mutants 
in which autophagy and proteasome activities were perturbed to ascertain if Hsp104A503S 
leveraged these pathways to inhibit proteotoxicity and if these deletions would affect 
Hsp104A503S suppression. We disrupted the genes encoding Atg8, which is crucial for 
autophagy induction and an essential component of autophagosomes (252-255), Rpn4, 
a transcription factor that promotes proteasome gene expression, and deletion reduces 
the level of the proteasome (256-258), and Ubr2, an E3 ubiquitin-ligase that targets 
Rpn4 and promotes its degradation, which when deleted leads to increase proteasome 
activity due to increase Rpn4 levels (259). Yeast with deletions or disruptions of ATG8, 
RPN4, and UBR2 are viable and were used to screen the dosage-sensitive gene library. 
The candidate genes were overexpressed in Δatg8Δhsp104 (autophagy-deficient), 
hsp104Δubr2 (proteasome-induced), and Δhsp104Δrpn4 (proteasome-reduced) yeast 
with Hsp104A503S or a pAG413Gal-ccdB vector control (Fig. 23). 
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Figure 23. Dosage-sensitive protein toxicity and suppression by Hsp104A503S is not 
typically affected in autophagy or proteasome-perturbed yeast strains.  
ATG8, UBR2, and RPN4 were knocked out with HSP104 deletion were screened for 
dosage-sensitive protein toxicity with a vector control and Hsp104A503S. Spotting assays 
were quantified as in Figure 6 using the rubric in Figure 5B. Red indicates increased 
toxicity, blue indicates suppression of toxicity in the ∆hsp104 background, and yellow 
indicates enhancement of toxicity in the ∆hsp104 background (n = 2-4 independent 
transformations). 
 
Hsp104A503S suppressed the toxicity of TDP-43, FUS, and α-synuclein in the 
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Δhsp104Δatg8, Δhsp104Δubr2, and Δhsp104Δrpn4 backgrounds. These findings are 
consistent with previous studies that found Hsp104A503S suppression of TDP-43, FUS, 
and α-synuclein toxicity did not require autophagy (207). We do observe a slight 
enhancement of toxicity of several proteins in the double mutant strains, especially TDP-
43 and FUS in the Δhsp104Δrpn4 strain where proteasome activity is reduced, however, 
rescue by Hsp104A503S is still robust (Fig. 23). Surprisingly, the Hsp104A503S-mediated 
suppression of dosage sensitivity was generally unaffected by these genetic disruptions. 
When the Hsp104A503S suppression of the toxicity of each gene in the autophagy-
defective and proteasome-perturbed yeast strains was plotted against Hsp104A503S 
suppression of the same game in Δhsp104 yeast, the extent of suppression was 
remarkably similar (Fig. 24A-C). The slopes of the linear regression fits for the 
Hsp104A503S toxicity suppression in Δhsp104Δatg8, Δhsp104Δubr2, and Δhsp104Δrpn4 
versus Δhsp104 were 0.806, 0.815, and 0.613 with coefficient of determination (r2) 
values of 0.590, 0.596, and 0.402 respectively, indicating high concordance in rescue. 
The lesser linear regression slope and correlation values for the Δhsp104Δrpn4 to 
Δhsp104 strain comparisons indicate that proteasome function may have an effect on 
gene toxicity itself because Hsp104A503S suppression is still very potent (Fig. 23). These 
data suggest that neither autophagy nor the proteasome are strictly required for 
Hsp104A503S to rescue overexpression toxicity.  
Alterations to the autophagy and proteasome systems did slightly affect the 
toxicity of genes in the Δatg8Δhsp104, Δhsp104Δrpn4, and Δhsp104Δubr2 strains 
expressing just the empty vector. The slopes of the linear regression fit for the toxicities 
of the dosage-sensitive genes in the Δhsp104Δatg8, Δhsp104Δubr2, and Δhsp104Δrpn4 
strains compared to the Δhsp104 strain with only the vector control were 0.898, 0.908, 
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and 0.738 with coefficient of determination (r2) values of 0.667, 0.665, and 0.432 for the 
respective comparisons (Fig. 24D-F). These comparisons show that when proteasome 
and autophagy pathways are affected, the basal toxicity of individual genes are generally 
very similar to the Δhsp104 strain but with some variability. The slope of nearly 1 and 
relatively high correlation for the Δhsp104Δatg8, Δhsp104Δubr2 plots indicate that gene 
toxicity is generally very similar between these strains and Δhsp104. The decrease in the 
correlation of the gene toxicity in the Δhsp104 and Δhsp104Δrpn4 comparison suggests 
that proteasome activity reduction can have a substantial effect on the toxicity of the 
genes when overexpressed (Fig. 24F). However, Hsp104A503S suppression of toxicity is 
still very robust in Δhsp104Δrpn4 yeast (Fig. 23), indicating that Hsp104A503S can still 
suppress the deleterious effects of dosage sensitivity even when proteasome function is 
limited.  
Some individual dosage-sensitive genes were significantly affected by ATG8, 
UBR2, or RPN4 deletion. Some notable examples are CDH1 and CLB6, two genes 
whose toxicity in the Δhsp104Δatg8 and Δhsp104Δubr2 background were enhanced 
(Fig. 23, 24D, E, 25A). As expected, Hsp104A503S expression still robustly suppressed 
the toxicity of CDH1 and CLB6 (Fig. 23, 25A). CDH1 toxicity was also increased in the 
Δhsp104Δrpn4 yeast strain and likewise Hsp104A503S suppression of toxicity was still 
effective, whereas CLB6 toxicity was unaffected when RPN4 was deleted. Curiously, 
ITT1 and HSF1 toxicities were abolished in the Δhsp104Δrpn4 strain (Fig. 24F). Another 
set of outliers are genes such as MRN1 and AKL1, which were less toxic when 
overexpressed in Δhsp104Δatg8, Δhsp104Δubr2, and Δhsp104Δrpn4 strains (Fig. 23, 
24E-F, 25A). As with CDH1 and CLB6, Hsp104A503S expression still rescued the dosage 
sensitivity of MRN1 and AKL1 (Fig. 23, 25B). However, the toxicity of some genes was 
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enhanced in the Δhsp104Δatg8, Δhsp104Δubr2 and Δhsp104Δrpn4 strains that 
Hsp104A503S co-expression was not able to fully suppress (Fig. 23). Notably, Hsp104A503S 
was not able to fully suppress toxicity of TPK3 and STE12 in the Δhsp104Δatg8 and 
Δhsp104Δrpn4 backgrounds (Fig. 23, 24A, B, 25C); however, genes like TPK3 and 
STE12 that are not suppressed were the rare exceptions. Overall, despite some 
examples, these data indicate that Hsp104A503S is rectifying dosage sensitivity-
associated toxicity directly and independent of autophagic and proteasomal function. 
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Figure 24. Dosage-sensitive protein suppression by Hsp104A503S is not greatly 
affected in autophagy and proteasome-perturbed yeast strains.  
The suppression of dosage-sensitive protein toxicity by Hsp104A503S in hsp104Δ (x-axis) 
plotted against Hsp104A503S suppression in A. Δ hsp104Δatg8 yeast; and B. 
Δ hsp104Δrpn4 (y-axis). The toxicity of dosage-sensitive genes in the Δhsp104 (x-axis) 
plotted against C. hsp104Δatg8 yeast; and D. Δ hsp104Δrpn4 (y-axis). 
 
 
 
Figure 25. Toxicity of some dosage-sensitive genes are affected by deletion of 
ATG8, UBR2, and RPN4.   
Representative spotting assays of dosage-sensitive genes in Δatg8Δhsp104, 
Δhsp104Δrpn4, and Δhsp104 yeast with vector control or Hsp104A503S. A. CDH1 and 
CLB6 displayed enhanced toxicity in the Δhsp104Δatg8 and Δhsp104Δrpn4 strains 
compared to Δhsp104 yeast. Hsp104A503S was still able to suppress the toxicity. B. 
MRN1 and AKL1 both displayed a decrease of toxicity in the Δhsp104Δatg8 
and Δhsp104Δrpn4 with the empty vector. C. The suppression of TPK3 and STE12 
toxicity by Hsp104A503S was diminished in the Δatg8Δhsp104 and Δhsp104Δrpn4 strains. 
 
2.2.9 Hsp104A503S Buffering Capacity Extends Beyond a Single Gene But Not To 
Entire Chromosomes 
Because of the tremendous ability of Hsp104A503S to suppress the toxicity of a 
single overexpressed gene, we were inspired to determine the dosage-sensitive protein 
buffering capacity of Hsp104A503S by simultaneously co-expressing multiple dosage-
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sensitive genes in yeast. We selected four genes, AKL1, RSP5, MRN1, and SFB3, to 
test in combination because of their differing toxicity scores and functions in the cell. 
AKL1 is a serine-threonine kinase in the Ark1-family of yeast kinases that regulates actin 
dynamics in cytoskeletal organization and endocytosis (260, 261). AKL1 was one of the 
most toxic gene in the library with a highest score of 5 in BYV and BYW but no toxicity in 
BYA (Fig. 6). RSP5 is an E3 ubiquitin ligase with many cellular functions in yeast, one of 
which is its essential role in targeting proteins misfolded by heat shock for proteolysis 
(261, 262). RSP5 only caused a mild growth defect with a score of 1.7 in BYV and no 
toxicity in BYA (Fig. 6). MRN1 is an RNA-binding protein that interacts with chromatin-
remodeling complexes and is important for mRNA maturation in yeast (263, 264). MRN1 
caused a moderate growth defect, score of 3.5, with full rescue by Hsp104A503S (Fig. 6). 
SFB3 (formerly LST1) is a Sec24p-family protein that dimerized with Sec23p to form part 
of the COPII vesicle coat that targets vesicles from the endoplasmic reticulum to the 
Golgi, including those that contain large oligomeric proteins and difficult protein cargoes 
(265, 266). SFB3 has moderate toxicity in BYV with a score of about 3 that is almost 
completely suppressed in BYA (Fig. 6). We found that Hsp104A503S was indeed able to 
suppress the toxicity of several pairs of co-expressed, unrelated, dosage-sensitive 
genes (Fig. 21A). Toxic individually, the combinations of AKL1 + RSP5, MRN1 + RSP5, 
SFB3 + RSP5, AKL1 + MRN1, and AKL1 + SFB3 were all very toxic to yeast expressing 
the vector control or Hsp104, but expression of Hsp104A503S provided very robust 
suppression of these five pair-wise combinations of dosage-sensitive genes (Fig. 26A). 
These results indicate that Hsp104A503S can have the capacity to buffer the toxicity of at 
least two genes simultaneously that have completely unrelated functions and possibly 
different mechanisms of dosage sensitivity. 
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Next, we tested whether Hsp104A503S could buffer growth defects in aneuploid 
yeast strains bearing entire chromosomal duplications. In this way, we could determine if 
there was an upper limit to the buffering capacity of Hsp104A503S. Specifically, we 
employed yeast strains that contained discrete, characterized, single chromosome 
duplications (267). However, Hsp104A503S expression was unable to suppress the toxicity 
of most aneuploid strains despite only very mild growth defect caused by each additional 
chromosome (Fig. 26B). Only against disome XII, did we observe a modest growth 
enhancement by Hsp104A503S (Fig. 26B). Despite the ability to suppress the toxicity of 
different pairs of unrelated genes, Hsp104A503S may not be able to suppress the growth 
defect caused by a single extra chromosome. Thus, Hsp104A503S appears well equipped 
to counter toxicity caused by the acute overexpression of one or two toxic genes. 
However, Hsp104A503S is unable to buffer toxicity connected with a subtler upregulation 
(~1.5-2-fold) in the expression of hundreds of yeast genes, with the possible exception 
of chromosome XII. 
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Figure 26. The buffering capacity of Hsp104A503S extends beyond single dosage-
sensitive genes.  
A. Representative serial dilution spotting with two dosage-sensitive genes co-expressed 
with an empty vector, Hsp104, or Hsp104A503S. Experiment performed by Courtney Buell. 
B. Representative serial dilution spotting assays with disomic yeast strains co-expressed 
with an empty vector, Hsp104, or Hsp104A503S. Experiment performed by Acacia Hori. 
 
2.2.10 Some Catalytically-inactive Dosage-Sensitive Genes Lose Toxic Phenotype 
To gain substrate-specific insight into Hsp104A503S dosage sensitivity 
suppression, we focused on several toxic protein substrates for further analysis. We 
sought to determine if the overexpression growth defect was connected to the enzymatic 
activity of the toxic protein. Thus, we focused on protein kinases and phosphatases, 
where it seems probable that excessive protein phosphorylation or dephosphorylation 
due to overexpression could readily lead to regulatory defects and toxicity. 
First, we focused on Ark1 and Akl1, which are members of the same family of 
serine-threonine kinases that regulate actin cytoskeleton dynamics in yeast (260, 268). 
The sequence identity in the kinase region of ARK1 and AKL1 is about 40%, with 
divergent C-terminal regions that are implicated in regulation of function (260). The C-
terminal regions of both proteins are predicted to be highly disordered and aggregation-
prone (Fig. 28C, D). Hsp104A503S rescue of Akl1 toxicity is accompanied by a reduction 
on Akl1 expression and slightly reduced Akl1 aggregation (Fig. 12, 16), whereas 
Hsp104A503S rescue of Ark1 is accompanied without an effect on protein expression but 
with reduced Ark1 aggregation (Fig. 12, 16). However, was the kinase activity of Akl1 
and Ark1 require for their toxicity?  
We generated catalytically-inactive mutants of these dosage-sensitive kinases 
Ark1K56A(260), and Akl1K78A(260) to determine if catalytic function was necessary for 
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dosage sensitivity (Fig. 27A). Ark1K56A and Akl1K78A were not toxic when overexpressed 
(Fig. 27B) despite high levels of expressed proteins (Fig. 29), demonstrating that kinase 
activity is a necessary component of dosage sensitivity for these kinases. These findings 
suggest that Hsp104A503S may also exert a direct effect on soluble Akl1 and Ark1, which 
might reduce their kinase activity. Since Hsp104A503V can unfold soluble substrates that 
bear an intrinsically unfolded domain, such as RepA-GFP (207, 208), we suggest that 
Hsp104A503S might also unfold Akl1 and Ark1 to reduce kinase activity and rescue 
toxicity. Further experiments are required to test this possibility. 
Next, we focused on Glc7 and Ppz1, which are related serine-threonine protein 
phosphatases with about 60% sequence identity in their catalytic regions (269). Ppz1 
differs from Glc7 with a long stretch of amino acids in the N-terminal region of the protein 
that is predicted to be unfolded natively but participates in interactions with binding 
partners (Fig. 27A, 28A,B) (270). Hsp104A503S rescues toxicity of Glc7 and Ppz1 without 
significantly affecting their expression level (Fig. 12), but does reduce their aggregation 
(Fig. 16). However, was the phosphatase activity of Glc7 and Ppz1 needed for their 
overexpression toxicity? To answer this question we generated Glc7H65K (271), and 
Ppz1R451L (272) phosphatase-dead variants (Fig. 27A). 
Ppz1R451L was robustly expressed but not toxic (Fig. 22B, 29), demonstrating that 
Ppz1 phosphatase activity was critical for overexpression toxicity. Interestingly, Glc7H65K 
was also robustly expressed but still toxic in BYV or BYW (Fig. 22B, 29). Thus, 
phosphatase activity was not required for Glc7 toxicity. Despite being catalytically 
inactive, Glc7H65K might still have the ability to form protein-protein interactions that are 
deleterious to yeast that are possibly disrupted by Hsp104A503S. Indeed, perhaps the 
aggregation of Glc7 (Fig. 16) is sufficient for toxicity, which is modestly reduced by 
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Hsp104A503S. However, Hsp104 also rescues HA-tagged Glc7 and Glc7H65K toxicity (Fig. 
12A, 27B), but does not affect aggregation of HA-tagged Glc7 (Fig. 16A). Thus, reduced 
aggregation of Glc7 does not appear to be required for rescue of Glc7 toxicity. Perhaps 
disruption of aberrant Glc7 protein-protein interactions by Hsp104A503S and aberrant HA-
tagged Glc7 protein-protein interactions by Hsp104 is critical to rescue toxicity. Further 
experiments are needed to test this possibility. 
Next, we explored whether the intrinsically disordered region of Ppz1 (Fig. 22A) 
was required for Ppz1 toxicity. Thus, an N-terminal truncation mutant of Ppz1 (Ppz1Δ1-
344) was constructed to investigate the importance of the intrinsically disordered region 
for dosage sensitivity. This unfolded region is also required for endogenous Ppz1 
function (270). Ppz1Δ1-344 remained toxic in yeast (Fig. 27B), and thus the disordered 
region was not essential for toxicity. Toxicity of this construct was reduced by 
introduction of the R451L mutation, demonstrating that the phosphatase activity of Ppz1 
is critical for toxicity (Fig. 27B). Hsp104A503S (but not Hsp104) rescued the toxicity of 
Ppz1 and Ppz1Δ1-344 (Fig. 27B). Thus, the disordered region of Ppz1 is not required for 
overexpression toxicity and is not required for rescue of toxicity by Hsp104A503S. We 
suggest that Hsp104A503S might also target soluble Ppz1 to rescue toxicity, possibly 
inhibiting phosphatase activity via binding site occlusion or forced unfolding. Increased 
protein turnover or degradation was not a cause of loss of toxicity because protein 
expression levels for Ppz1Δ1-344 and Ppz1Δ1-344R451L were substantial and consistent 
between strains (Fig. 29). 
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Figure 27. Deactivated dosage-sensitive proteins can lose toxicity.  
A. Catalytically inactive versions of dosage-sensitive proteins, Glc7H65K, Ppz1R451L, 
Ark1K56A, and Akl1K78A and truncation mutants, Ppz1Δ1-344 and Ppz1Δ1-344R451L, were 
generated to determine importance of protein function to dosage sensitivity. B. 
Representative serial dilution spottings with wild-type and null genes both untagged and 
HA-tagged. 
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Figure 28. Ppz1, Ark1, and Akl1 are all predicted to have large unfolded stretches.  
FoldIndex prediction of the foldedness of a protein based on hydrophobicity and net 
charge (273). Predictions are provided for A. Glc7; B. Ppz1; C. Ark1; and D. Akl1. 
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Figure 29. Kinase- and Phosphatase-inactive proteins were expressed in Vector 
control, Hsp104, and Hsp104A503S strains.  
A. Representative Western blots of HA-tagged Glc7, Ppz1, Ppz1Δ1-344, Akl1, and Ark1 
with the their respective null mutants in Δhsp104 yeast expressing an empty vector, 
Hsp104, or Hsp104A503S. Pgk1 was used as the loading control. 
 
2.2.11 Hsp104A503S Directly Decreases Ppz1 Phosphatase Activity in vitro  
To determine if Hsp104A503S can target and deactivate soluble, active protein, we 
purified Ppz1 from E. coli (274, 275) (Fig. 30A). We then assessed Ppz1 phosphatase 
activity in the presence or absence of Hsp104 or Hsp104A503S. The phosphatase-dead 
variant, Ppz1R451L, was also purified and used as a negative control for Ppz1 (Fig. 30A). 
Purified Ppz1 and Ppz1R451L were mixed with purified Hsp104 or Hsp104A503S and para-
nitrophenyl phosphate (pNPP) substrate to determine Ppz1 phosphatase activity in 
assay conditions similar to those used to test unfolding of RepA-GFP by Hsp104 (183) 
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(Fig. 30B). pNPP is a chromogenic, artificial substrate for many phosphatases, including 
serine/threonine phosphatases like Ppz1. Phosphatases hydrolyze the pNPP, liberating 
a phosphate and leaving a para-nitrophenol that absorbs at 405 nm. Hsp104 incubated 
with Ppz1 slightly decreased the activity of the phosphatase by approximately 15% 
compared to Ppz1 alone. Remarkably, Hsp104A503S substantially decreased Ppz1 activity 
by over 75% (Fig. 30B, C). Indeed, Ppz1 alone and Ppz1 incubated with Hsp104 had 
activity levels that were within error, whereas, Ppz1 incubated with Hsp104A503S had 
activity that was similar to the negative control, catalytically-inactive Ppz1R451L (Fig. 30B, 
C). The in vitro inhibition of Ppz1 by Hsp104A503S demonstrates that there is a direct 
interaction between Hsp104A503S with functional Ppz1 that is sufficient to decrease its 
phophatase activity, which is necessary for dosage sensitivity. 
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Figure 30. Hsp104A503S suppresses Ppz1 phosphatase activity in vitro.  
A. Coomassie stain of E. coli purified Ppz1 and Ppz1R451L separated by SDS-PAGE. B. 
0.7 µM purified recombinant Ppz1 was incubated with buffer control or 4mM ATP and 
2.1 µM hexameric Hsp104, or Hsp104A503S. Phosphatase activity was measured with 10 
µM pNPP substrate over the course of 15 minutes at room temperature in a microplate 
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reader. Phosphatase activity of Ppz1R451L with 4 mM ATP was also measured. 
Phosphatase activity normalized to Ppz1 activity at 15 minutes. (Mean ± s.e.m., n = 4 
technical replicates). C. Phosphatase activity after 15 minute was normalized to Ppz1 
activity in buffer control (Mean ± s.e.m., n = 4 technical replicates , one-way ANOVA 
using Fisher’s LSD multiple comparisons test, **** = p < 0.0001).  
 
2.2.12 Hsp104A503S Ablates v-Src Toxicity in Yeast 
Based on the ability of Hsp104A503S to combat the toxicity of dosage-sensitive 
genes associate with diverse neurodegenerative diseases as well as diverse dosage-
sensitive yeast genes, we investigated its ability to suppress the phenotype caused by 
an overexpressed oncogene. Oncogenes are cancer-associated genes that are mutated 
or misregulated, which often leads to hyperactivation or overexpression that can 
contribute to malignancy. We employed v-Src, a Rous sarcoma virus gene encoding a 
tyrosine kinase that is oncogenic in a variety of cell types chickens (276). However, in S. 
cerevisiae, v-Src expression causes the opposite phenotype--stalled cell cycle 
progression leading to large unbudded cells, presumably due to tyrosine phosphorylation 
that is hypothesized to cause aberrant downstream signaling resulting in disruption of 
mitosis (277, 278). v-Src is a specific client of Hsp90 chaperones, which interact with the 
nascent v-Src protein to stabilize the protein, ensure proper folding, and insertion into 
the plasma membrane, thus activating the protein (277). Deletion of yeast Hsp90 gene, 
HSC82, abolishes v-Src toxicity, decreases v-Src expression levels, and decreases the 
amount of tyrosine phosphorylation (277). 
Remarkably, like with yeast dosage-sensitive genes, Hsp104A503S (but not 
Hsp104) co-expression robustly suppressed the very severe v-Src growth defect (Fig. 
31A). Unlike with most dosage-sensitive yeast genes, Hsp104A503S expression 
significantly reduced the protein expression levels of v-Src by over 60% (Fig. 31B, C). 
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Hsp104A503S overexpression also resulted in an approximately 40% decrease of 
phosphotyrosines in yeast (Fig. 31D, E). These results mirror phenotypes observed in 
yeast with HSC82 deletions, in which v-Src toxicity is also suppressed. Hsp104A503S 
overexpression might act in a similar manner as HSC82 deletion, by directly opposing 
the activity of Hsp90, which stabilizes, folds, and directs v-Src to the plasma membrane. 
Thus, Hsp104A503S may remediate v-Src toxicity in yeast by unfolding or preventing the 
folding of functional v-Src, which can then facilitate protease digestion. The reduction of 
cytosolic v-Src, may then decrease the amount of potentially deleterious tyrosine 
phosphorylation. 
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Figure 31. Hsp104A503S suppresses v-Src toxicity and activity in yeast.  
A. Representative serial dilution spotting with v-Src co-expressed with an empty vector, 
Hsp104, or Hsp104A503S. B. Western blot detecting induced Hsp104 and v-Src protein 
levels in Δhsp104 yeast expressing an empty vector, Hsp104, or Hsp104A503S. Pgk1 was 
used as the loading control. C. Western blot detecting induced phosphotyrosine protein 
levels in Δhsp104 yeast expressing an empty vector, Hsp104, or Hsp104A503S. Pgk1 was 
used as the loading control. D. Quantification of Pgk1-normalized v-Src expression in the 
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vector, Hsp104 and Hsp104A503S strains (Mean ± s.e.m., n = 4-6 independent 
transformations and inductions, One-way ANOVA using Fisher’s LSD Test, **** = p < 
0.0001). E. Quantification of Pgk1-normalized phosphotyrosine expression in the vector 
control, Hsp104 and Hsp104A503S strains (Mean ± s.e.m., n = 4-6 independent 
transformations and inductions, One-way ANOVA using Fisher’s LSD Test, *** = p < 
0.001, **** = p < 0.0001). 
 
2.3 Discussion 
In this chapter, we show that Hsp104A503S displays unprecedented efficacy as a 
suppressor of dosage sensitivity. Hsp104A503S suppressed the toxicity of the vast 
majority, over 95%, of all genes tested, from the very toxic to those with more moderate 
toxicity. We determined that Hsp104A503S was not simply depressing the protein 
expression levels to rescue dosage sensitivity but likely had a more active role. We 
found that while dosage-sensitive genes were not producing proteins that formed 
amyloid, they did form large, SDS-soluble aggregates that were associated with toxicity. 
Typically, Hsp104A503S was able to prevent the formation of these aggregates whereas 
Hsp104 was not, although there were exceptions as discussed above. We probed the 
ATPase and substrate binding modalities of Hsp104A503S and discovered that it is more 
sensitive to mutations that impede substrate binding at either NBD than mutations that 
disrupt ATPase activity at either NBD. Single mutations to either substrate binding loop 
almost completely nullified Hsp104A503S potentiation, but mutations to Walker B motif 
residues in individual NBDs were well tolerated. We revealed that Hsp104A503S 
suppression of dosage sensitivity was not dependent on autophagy pathways or 
proteasome function. By interrogating its buffering capacity, we found that Hsp104A503S 
was able to suppress several combinations of two dosage-sensitive genes expressed on 
different plasmids, but that it was ill equipped to counter the more subtle and system-
wide proteome disruption caused by aneuploidy. To gain more granular insight into the 
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process by which Hsp104A503S prevents dosage sensitivity, we purified a dosage-
sensitive protein, Ppz1, and demonstrated that Hsp104A503S, but not Hsp104, could 
greatly diminish Ppz1 phosphatase activity in vitro, which is essential for the toxic 
overexpression phenotype in vivo. Lastly, we show that Hsp104A503S was able to robustly 
suppress the toxicity of a potent oncogene, v-Src, and decrease the abundance of 
protein and its activitt, which may restore proper cycle progression. 
In totality, these finding establish Hsp104A503S as a potent suppressor of dosage 
sensitivity in yeast. Without the aid of the autophagy and proteasome pathways, 
Hsp104A503S disrupts aggregation formation and can directly inhibit protein activity to 
rescue protein toxicity due to overexpression. 
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CHAPTER 3: CONCLUSIONS AND FUTURE DIRECTIONS 
3.1 Conclusions 
We demonstrate that Hsp104A503S is an effective agent for combating toxicity 
associated with protein overexpression. The suppression of over 95% of dosage-
sensitive genes by Hsp104A503S is unprecedented in scope. Of the 120 genes that had a 
toxicity score above 0.75, Hsp104 rescued the dosage sensitivity of all but 3 genes, 
KAR1, MUK1, and TRM5. Moreover, the effect of Hsp104A503S co-expression on dosage 
sensitivity was extremely robust. Of the 48 moderate-to-high toxicity genes with scores 
of 2.5 or above, Hsp104A503S reduced the toxicity of these genes by 2 or more for all but 
2 genes, ITT1 and KAR1, proving that it is able to suppress toxicity of even the most 
toxic genes. 
  We generated HA-tagged fusions to probe the expression and aggregation 
phenotypes of the overexpressed, dosage-sensitive proteins in yeast when Hsp104, 
Hsp140A503S, or a vector control was also expressed.  Western Blot analysis showed that 
although Hsp104A503S had a slight effect on protein expression, the extent of rescue was 
not correlated to the decrease of protein expression. Thus, limiting the amount of protein 
expressed was not the sole means of preventing protein overexpression toxicity. 
Likewise, none of 18 dosage-sensitive proteins tested formed amyloid—although some 
did form detergent-soluble, unstructured aggregates that were readily dissolved by 
Hsp104A503S. The prevention or dissolution of these labile aggregates was correlated to 
suppression of dosage sensitivity. In some cases, Hsp104 could reduce this aggregation 
without affecting toxicity, which indicates that non-aggregated, soluble protein species 
may be causing toxicity. Hsp104A503S, but not Hsp104, may be able to further denature 
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these soluble toxic species—potentially through exposed hydrophobic regions that are 
endemic to dosage-sensitive proteins, and a common modality for forming aberrant 
inter-protein interactions that can lead to aggregation. This enhanced ability of 
Hsp104A503S (compared to Hsp104) to unfold soluble substrates is a feature consistent 
with previous studies (207, 208) and may be leveraged to prevent protein 
overexpression-induced toxicity. 
 To determine if other cellular pathways were involved or necessary in the 
Hsp104A503S suppression of dosage sensitivity we screened in several yeast knockout 
mutant strains where autophagy and proteasome function were affected. Deletion of 
ATG8, which disrupted autophagosome formation, UBR2, which induced proteasome 
activity, and RPN4, which reduced proteasome function, did not alter that ability of 
Hsp104A503S to suppress dosage sensitivity in yeast. Although the basal toxicity of some 
dosage-sensitive proteins were affected in the autophagy-deficient and proteasome-
perturbed strains, Hsp104A503S expression heartily suppressed dosage lethality in almost 
all cases. These results strongly suggest that protein degradation pathways are not 
adopted by Hsp104A503S to quell toxicity due to protein overexpression. 
Next, we sought to elucidate the characteristics of Hsp104A503S that were most 
important for its potentiation against dosage-sensitive proteins. Mutational analysis 
showed that while substrate binding to pore loops was indispensable for Hsp104A503S to 
rescue toxicity of diverse proteins, the potentiated protein was still very effective when 
mutations to single NBDs ablated ATP hydrolysis. Moreover, mutations to the individual 
NBD did not seem to greatly affect the repertoire of proteins that Hsp104A503S could 
suppress. WB1 and WB2 variants could prevent the toxicity of an almost completely 
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overlapping set of genes, indicating that perhaps certain protein substrates are less 
taxing on Hsp104A503S, not requiring full activity. 
We found that Hsp104A503S can attenuate the toxicity of at least two different 
genes with different functions when they are overexpressed simultaneously. The robust 
suppression of the combination of AKL1, one of the most toxic genes, and SFB3, a 
moderate-high toxicity gene, was even more striking because two proteins are involved 
in completely different processes and localized to different compartments in the cell. 
Akl1, is a cytoplasmic kinase that is involved in actin cytoskeleton organization (261) and 
Sfb3 is a part of the COPII vesicle coat assembly that targets vesicles from the ER to the 
Golgi(265, 266). Yet even when both were overexpressed in the same yeast, 
Hsp104A503S was able to suppress the toxicity of both genes. 
To gain more insight into the mechanism of dosage sensitivity and how 
Hsp104A503S may act to inhibit it, we generated and expressed inactivated versions of 
several toxic genes. We showed that dosage sensitivity was dependent on the 
enzymatic activity of Ppz1, Ark1, and Akl1. Thus, we wondered whether Hsp104A503S 
might engage soluble toxic proteins and inactivate them, perhaps by forced unfolding as 
with model RepA-GFP substrate (207, 208). We demonstrated that purified, functional 
Ppz1 was inhibited by Hsp104A503S in vitro, significantly decreasing Ppz1 phosphatase 
activity far more than Hsp104. Thus, Hsp104A503S can directly inhibit Ppz1. We suggest 
that in addition to preventing formation of labile, SDS-soluble aggregates Hsp104A503S 
can also suppress dosage sensitivity by directly unfolding or otherwise deactivating the 
toxic protein.  
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However, further experiments are needed to determine if Hsp104A503S is fully 
unfolding Ppz1 to inactivate it or whether it is only partially engaging the substrate—
enough to sterically hinder the active site and thus inhibit phosphatase activity. The 
potentially enlightening experiment would be to include with Hsp104A503S a modified 
version of GroEL, GroELD87K, a ‘trap’ variant that can bind denatured substrates but not 
release them due to its deficiency in ATP hydrolysis (279). Binding of Ppz1 to “trap” form 
of GroEL would indicate that the phosphatase is indeed unfolded and will help clarify if it 
is fully unfolded by Hsp104A503S. Likewise, the unfolding activity of Hsp104 can be 
coupled to proteolytic degradation to demonstrate substrate translocation through the 
central pore (280, 281). We can generate the HAP variant of Hsp104A503S, in which the 
G739, S740, K741 residues are mutated to IGF, to foster physical interaction with the 
bacterial protease, ClpP (249). In this complex, the Hsp104A503S-HAP would engage and 
unfold substrate, directly translocating the substrate into the ClpP proteolytic chamber 
where it is degraded into small peptide fragments (282). SDS-PAGE with Coomassie 
staining or immunoblotting would provide a clear picture of whether Ppz1 was unfolded 
by Hsp104A503S and degraded by ClpP. Pairing Hsp104A503S with either GroELD87K or 
ClpP would provide more convincing evidence that Hsp104A503S is indeed unfolding toxic 
substrates via polypeptide translocation. 
Finally, we show that Hsp104A503S can even suppress the activity of a human 
oncogene that is dosage sensitive in yeast. Although in chickens, v-Src promotes 
oncogenesis, in yeast, it has the opposite effect of stalling cell cycle progression(278). 
However, Hsp104A503S strongly suppressed this toxic phenotype in yeast. Thus proving 
that in principle it (and perhaps other engineered protein unfoldases) may have 
widespread applications in a variety of human diseases connected with protein 
overexpression. 
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Paradoxically, if Hsp104A503S is able to identify and unfold toxic, dosage-sensitive 
substrates in nearly every instance, how does it avoid other soluble proteins? Hints of 
this lack of specificity are present in the ever so slight defect in growth caused by 
Hsp104A503S expression alone in the BYA strain, suggesting a basal level of Hsp104A503S 
promiscuity in substrate selection which can be deleterious. This slight toxicity might 
have exerted negative selection pressure for any amino acid at the 503 position but 
alanine in yeast, which would explain why such a beneficial mutation against 
overexpression toxicity was not adopted in yeast. Moreover, this mild toxicity is more 
severe when yeast are grown at 37ºC and under mild thermal stress, whereas Hsp104 is 
not toxic in these conditions. Our findings suggest that toxicity due to overexpression of 
a single yeast gene is a rare form of stress, which may not have been a strong selective 
force dictating Hsp104 sequence space. The inability for yeast to fully regulate internal 
temperature makes them particularly susceptible to environmental changes that induce 
protein-folding stress that could induce deleterious Hsp104A503S activity. These potential 
off-target effects leading to a decrease in growth could be remedied by iterative 
mutations of Hsp104A503S to derive variants with enhanced activity towards specific 
substrates of interest, while limiting interactions with other substrates and thereby 
eliminating the growth defect. 
3.2 Future directions 
The surprising efficacy of Hsp104A503S in combating nearly every dosage-
sensitive protein suggests that Hsp104A503S can potentially be leveraged to treat many 
other diseases caused by protein overexpression. Beyond the use in treating 
neurodegenerative disease such as AD, PD, HD, and ALS which feature accumulations 
of aggregated protein, any disease in which protein regulation is lost and aberrant 
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overexpression promotes disease pathogenesis would be a viable candidate for 
treatment with Hsp104A503S. For example, many cancers feature overexpression of 
protein including transcription factors, growth factors, and metabolic enzymes, all of 
which could be targeted by Hsp104A503S for activity suppression. The promising result of 
Hsp104A503S decreasing v-Src toxicity in yeast leads to the next steps of determining 
whether it can be effective in cell culture and animal models of cancer to limit cellular 
proliferation, return cells back to a more differentiated state, or counter oncogenic 
phenotypes (reverse EMT, decrease telomerase expression, decrease colony formation, 
restore contact inhibition, etc).  
Yet, expressing Hsp104 in human patients is not without substantial challenges, 
the primary of which is the high likelihood that expressing foreign yeast proteins in 
humans would lead to a significant and potentially deadly immune response. Limited 
expression of Hsp104 in the brain may be more easily tolerated due to Central Nervous 
System (CNS) immune privilege, in which destructive, inflammatory T-cell responses 
common in the periphery are dampened in certain areas of the CNS (283). The 
effectiveness of Hsp104A503S in reversing cancer phenotypes presents an exciting proof-
of-principle to inform future work. If shown to be effective against models of cancer, 
other proteins with lower immunogenicity such as human protein-remodeling factors or 
unfoldases like Hsp70 and Hsp110 could be developed and engineered to gain activity 
akin to Hsp104A503S in suppressing dosage sensitivity and prevent oncogenesis. 
Retroviral delivery or CRISPR-Cas9 editing to introduce engineered human proteon-
remodeling factors to throttle the effects of overexpressed and aggregated protein in 
targeted cell types would be an exciting next step. 
Two chaperones that were tested in this study, Ssa1 and Hsp82, were not 
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effective at suppressing protein overexpression toxicity. However, we only 
overexpressed wild-type versions of these respective proteins with a moderate increase 
in protein levels in a background that already feature substantial expression levels of 
each. That neither wild-type Ssa1 nor Hsp82 were active against dosage-sensitive 
proteins should not disqualify them for future studies because wild-type Hsp104 was 
also unable to suppress dosage sensitivity in the same system. Rather, the results from 
this study suggest that engineered mutants of Hsp82 or Ssa1 might be uncovered that 
are effective against a wide spectrum of dosage-sensitive proteins. Moreover, 
chaperones of the Hsp40 or Hsp110 families could be tested for elevated dosage 
sensitivity suppression capacity. Like Ssa1 and Hsp82, Hsp40 and Hsp110 family 
chaperones are also conserved in humans and any gains made in potentiating these 
enzymes in yeast could be directly translatable to humans. Furthermore, these studies 
would be particularly illuminating to determine the substrate recognition and binding 
potential of these chaperones. It would be interesting to learn if engineered version of 
these proteins also had a broad substrate repertoire like Hsp104A503S or if they were 
narrower, tailored to specific substrates or classes of substrates.  
In this study, Ppz1 phosphatase activity was shown to be essential for its dosage 
sensitivity in yeast and we demonstrate that Hsp104A503S directly inhibited the 
phosphatase activity of Ppz1 in vitro, which we proposed was the mechanism by which 
Hsp104A503S curbed Ppz1 toxicity, but is this what actually happens cells? An interesting 
next step would be to test to see if protein phosphorylation in yeast overexpressing Ppz1 
was affected by coexpression of Hsp104A503S. A proteomics approach utilizing mass 
spectrometry could accurately identify proteins whose phosphorylation state were 
altered by Ppz1 expression and whether Hsp104A503S expression could affect the 
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quantity or distribution of protein modifications. This would provide more direct evidence 
that Hsp104A503S attenuation of Ppz1 activity in vivo was the mechanism by which it 
suppressed Ppz1 toxicity. A phosphoproteomics approach could also be employed to 
test the many other kinases and phosphatases that are dosage-sensitive (Fig. 10A) to 
determine if the hyperactivity of these proteins are also abrogated by Hsp104A503S as a 
means of limiting toxicity associated with overexpression of these proteins.  
It is particularly interesting to note that not all members of a class of proteins are 
dosage-sensitive. For example, in yeast, there are 3 members of the ARK1 kinase 
family: ARK1, AKL1, and PRK1. Ark1 and Akl1 were two of the most toxic dosage-
sensitive proteins in our system. Despite sharing over 70% sequence identity with ARK1 
in the kinase domain, having overlapping function, and similar architecture with an 
intrinsically unfolded C-terminal region (268), PRK1 overexpression in our system was 
not toxic. More than the isolated function of proteins must then determine dosage 
sensitivity. Likewise, Ppz2 and Ppz1 are highly similar proteins, sharing 94% sequence 
identity in the phophatase domain of the protein with 43% sequence identity elsewhere 
and even boasting overlapping functions (269) and yet only Ppz1 is toxic when 
overexpressed. How is it that genes with such similar functions and features, even 
sharing high sequence homology could be drastically different in toxicity when 
overexpressed? Characterizing the difference between Ppz1 and Ppz2 or Ark1 and Prk1 
could reveal the factors that are most important for determining whether a gene is 
dosage-sensitive. Moreover, understanding these differences could be useful in 
determining how the deleterious effects of overexpression can be mitigated by cells with 
or without potentiated Hsp104. 
The toxicity of the main outliers in this study are also worthy of consideration. 
 104 
 
ITT1 and KAR1 are two very toxic genes that are almost completely resistant to 
Hsp104A503S activity and TRM5 is a gene whose toxicity is enhanced by Hsp104A503S 
expression. Of the 48 moderate-to-high toxicity genes with scores of 2.5 or above, ITT1 
and KAR1 were the two genes that were not substantially rescued, although ITT1 toxicity 
was slightly decreased by Hsp104A503S expression. ITT1 (Initiation of Translation 
Termination) encodes a protein that can regulate the efficiency of translation termination 
(284). Overexpression of ITT1 was shown to decrease the efficiency of translation 
termination, presumably by increase binding to polypeptide chain release factors which 
inhibits translation termination and results in significant increases in read-through of 
nonsense and legitimate stop codons (284). The read-through of stop codons might lead 
to the increase production of unfolded or misfolded proteins that exceeds the buffering 
capacity of Hsp104A503S. Unlike with other dosage sensitive proteins, which Hsp104A503S 
directly engage to suppress its deleterious effects, ITT1 overexpression may produce 
misfolded substrates that Hsp104A503S bind instead of Itt1, leaving it to continue 
promoting read-through of stop codons and the production of spurious protein products. 
Indeed, Hsp104A503S was also typically unable to buffer toxicity conferred by aneuploidy, 
which likely involves modest overproduction of hundreds of gene products. Explanation 
for why the toxicity Kar1, a protein involved spindle pole body formation and duplication 
during karyogamy and mitosis (285), is not rescued by Hsp104A503S is not as clear, 
especially when so many of the other dosage-sensitive are also spindle pole body 
components or otherwise involved in cell division. Likewise, how Hsp104A503S expression 
enhances the toxicity of TRM5, which encodes a tRNA m1G37 methyltransferase (286), 
is also not clear. 
Is there a unifying theme to what makes genes toxic when overexpressed? 
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Several studies hypothesize that dosage-sensitive proteins are involved in large 
complexes with specific stoichiometry that is disrupted by overexpression (287), but that 
theory has been largely discredited for dosage sensitivity caused by overexpression—
although it is still likely the cause of growth disruption for gene underexpression or 
haploinsufficiency (42). The findings of this study suggest that some dosage-sensitive 
proteins are toxic because its elevated enzymatic activity is deleterious and not the 
result of a passive process such as the balance hypothesis would suggest (239, 288). 
When mutated to the inactive form, Ppz1, Ark1, and Akl1 lost their dosage sensitivity 
toxicity phenotype. This finding suggests that the normal function of some proteins is 
essential for dosage sensitivity and Hsp104A503S can prevent this by decreasing protein 
activity levels potentially though unfolding soluble protein (Fig. 32A). 
Other recent studies also suggest that mass-action-driven interaction promiscuity 
through interactions with intrinsically disordered regions within proteins is the most likely 
explanation for the dosage sensitivity of overexpressed proteins. This theory is also 
supported within the context of our hyperactivity model because aberrant interactions 
with catalytically active dosage-sensitive proteins may result in detrimental 
consequences. For example, Ppz1 has an intrinsically unfolded N-terminal region that is 
essential for protein function which can be myristoylated and is thought to be important 
for forming protein-protein interaction to specify function (270). Overexpression of Ppz1 
could lead to overwhelming the regulation of this protein, especially in the intrinsically 
unfolded region, resulting formation of unregulated promiscuous interactions with non-
native client proteins.  Ppz1 may then dephosphorylate non-canonical regulatory sites 
resulting in unwanted activation or inhibition of crucial enzymes. However, we found that 
this region of Ppz1 was not required for overexpression toxicity. Nonetheless, the high 
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enrichment of intrinsically unfolded regions and linear motifs in dosage-sensitive proteins 
is a likely modality for these toxic proteins to form deleterious protein-protein 
interactions.  
Exposed disordered regions in dosage-sensitive proteins provide low specificity 
binding surfaces that could also foster aberrant and promiscuous interactions that can 
lead to toxic aggregate or oligomer formation, sequestration of essential proteins through 
non-native interactions, diversion of chaperones, and even formation of liquid-liquid 
phase separations (LLPS). Hsp104A503S is well adapted to also tackle each of these 
possibilities. Hsp104A503S was shown to be very effective (much more so than Hsp104) at 
dissolving dosage sensitivity-associated protein aggregates in cells and also in vitro (Fig. 
12A, B) (207, 208), so if dosage-sensitive proteins were forming aggregates, 
Hsp104A503S would be more capable of dissolving them (Fig 32B). Moreover, the 
enrichment in linear motifs and intrinsically disordered regions in dosage-sensitive 
proteins, which can cause toxic oligomer or aggregate formation, can also facilitate 
promiscuous interactions with non-native binding partners and even trapping these 
proteins within aggregated structures. Hsp104A503S can mediate the release these 
speciously bound proteins by disrupting oligomeric complexes and dissolving 
aggregates (Fig. 33C). However, if dosage-sensitive proteins are diverting other 
molecular chaperones from their intended substrates, Hsp104A503S can provide an 
additional buffer for these toxic proteins (Fig. 33D). Hsp104A503S is capable of refolding 
aggregated and denatured substrates, even without collaboration of Hsp40 and Hsp70 
co-chaperones in vitro (207, 208), its elevated activity against misfolded and 
aggregation-prone substrate, would unencumber the proteostasis network. 
Lastly, the intrinsically-disordered regions endemic to dosage-sensitive proteins 
could be undergoing inappropriate and toxic LLPS (160). Indeed, in addition to the high 
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propensity of these toxic proteins to have intrinsically-disordered regions compared to 
the genome, another highly common feature are prion-like domains (Fig. 11A). Prion-like 
domains feature high polar uncharged amino acid and glycine content (289), which can 
also drive LLPS (157, 158, 290-292). Recent work has shown that for the dosage-
sensitive protein, Mip6, toxicity was correlated with induction of a LLPS and growth was 
restored when the foci were dissolved (160). This work suggest that SDS-soluble 
aggregates we detected in the filter retention (Fig 16A, B) may actually be labile, phase-
separated liquid aggregates and Hsp104A503S was able to suppress the toxicity of these 
proteins by fully dispersing these droplet structures, which may be correlated with 
toxicity (Fig. 32E). 
The ability for Hsp104A503S to suppress the toxicity of nearly every dosage-
sensitive gene opens up the possibility that Hsp104A503S can be used to treat many 
human diseases in which increased gene dosage can be a contributor to disease 
pathology. Moreover, the multitude of potential mechanisms by which Hsp104A503S can 
employ to overcome proteotoxicity in diseases in which proteostatic integrity is lost, 
provides great flexibility in its application to treat neurodegenerative disease such as AD, 
PD, HD, and ALS. Further study will be required to determine whether or not 
Hsp104A503S or related engineered proteins can be translated in clinical settings to 
provide lasting impact in treating human diseases. 
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Figure 32. Hsp104A503S may suppress dosage sensitivity in many distinct ways. 
A. A protein can cause dosage sensitivity when overexpression leads to decreased 
regulation and in increased activity of the protein resulting be spurious and off-target 
effects. Hsp104A503S may bind the overexpressed toxic protein through exposed 
disordered regions, unfold it, and reduce deleterious activity. B. Some proteins when 
overexpressed will form oligomeric species or aggregates that have a toxic gain-of-
function. Hsp104A503S can bind and dissolve these oligomers and aggregates to allow 
them to refold to their native form. C. Dosage sensitive proteins are enriched in linear 
motifs and intrinsically-disordered regions, which may be able to form low specificity, 
promiscuous interactions with non-native binding partners or trap essential proteins in 
aggregates. Hsp104A503S can unfold these misfolded proteins and release their binding 
partners. D. Dosage sensitive proteins can also have the indirect effect of diverting other 
molecular chaperones from their intended substrates. Hsp104A503S can provide an 
additional buffer for these proteins that are misfolded and aggregation-prone, thereby 
empowering the proteostasis network. E. The intrinsically disordered regions and prion-
like domains enriched in dosage-sensitive proteins can also form intermolecular 
interactions to drive LLPS events that are correlated with dosage sensitivity. Hsp104A503S 
can mediate the dispersion of these phase-separated droplets. 
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CHAPTER 4: METHODS 
4.1 96-well Plate Yeast Transformation 
Modified from published protocols (293). 250-500 ng of selected plasmid DNA 
from the FLEXgene library (~5,500 genes and ORF’s in a galactose-inducible 
expression pBY011 plasmid system, (294)) were individually plated into the wells of 96-
well cell culture plates (Denville T1096). For each 96-well plate of DNA to be 
transformed into yeast, 200ml of YPD were inoculated with an overnight culture of yeast 
at OD600 of 0.1 and grown with shaking (250 rpm for all steps) at 30 ºC until OD600 
measured 0.8-1.0. Yeast cultures were pelleted by centrifugation (5 minutes at 1500 g 
for all steps), supernatant was decanted, and the pellet was resuspended in 10 ml of 
sterile water. The yeast slurry was pelleted by centrifugation, washed in 0.1 M lithium 
acetate (LiOAc) in TE (10 mM Tris, pH 7.5 and 1mM EDTA) and pelleted by 
centrifugation. The yeast was then resuspended in 7ml 0.1M LiOAc/TE and incubated 
for 15 minutes with shaking at 30 ºC. β-mercaptoethanol was added to a final 
concentration of 0.1M and incubated for 15 minutes with shaking at 30 ºC. Boiled and 
chilled, sonicated salmon sperm (Agilent 201190) was added to yeast slurry to 3% final 
concentration. 50 µl yeast slurry was dispensed into to each well by multichannel pipette 
or liquid handling robot. 125 µl transformation mix (0.1M lithium acetate, 40% PEG 3350, 
10% DMSO) was added to each well by multichannel pipette or liquid handling robot, 
mixed thoroughly, and then the plates were incubated for 30 minutes at room 
temperature. Yeast were then heat shocked for 30 minutes at 42 ºC and pelleted by 
centrifugation. The PEG solution was forcefully decanted over a liquid waste receptacle 
and 100 µl appropriate selective, synthetic media supplemented with glucose was added 
to each well. Yeast were pelleted by centrifugation, the supernatant was decanted, and 
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200 µl synthetic media supplemented with glucose was added to each well. Plates were 
incubated for 48 hours at 30 ºC to allow for selection and growth of transformed yeast. 
Small white yeast colonies should be visible at the bottom of each well. 
4.2 Yeast Spotting Assays 
Transformed yeast were resuspended by vigorous pipetting and 5-10µl 
suspension was added to raffinose-supplemented synthetic media in 96-well tissue 
culture plates (200 µl per well) then grown overnight at 30°C without shaking. Cultures 
were 5-fold serially diluted into new 96-well tissue culture plates with sterile water and 
spotted using a 96-bolt blot replicator (V&P Scientific Cat. No. VP 404) onto 2% agar-
solified synthetic media with glucose or galactose in Omnitrays (Thermo 242811). Plates 
were grown inverted for 2 days at 30°C or 3 days at room temperature, photographed 
with a Canon SD1200 IS digital camera on an enlargement stand, and scored by the 
scale given in Fig. 1B. 
4.3 Analysis of Dosage-sensitive Gene Features 
 Dosage-sensitive gene functions (Fig. 10A, B) and component Gene Ontology 
(GO) terms were obtains using the SGD Gene Ontology Slim Mapper 
http://yeastgenome.org/cgi-bin/GO/goSlimMapper.pl 
 Dosage sensitive gene feature enrichment correlation (Fig. 11A) was performed 
by Oliver King as described (4). Briefly, for each feature tested, the correlation was 
determined for the gene to that feature. A tenfold cross-validation experiment was used 
to determine the predictiveness of each feature to the dosage-sensitive genes. The 
mean area under a receiver operating characteristic (ROC) curve for each of the cross-
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validation experiments was used to determine the enrichment of each feature in the 
dosage-sensitive gene set. The following features were used: 
• From the SGD table protein_properties.tab, but with counts of each AA changed 
to percentages, to remove most (but maybe not all) of their correlation with 
PROTEIN.LENGTH: 
o PI (isoelectric point) 
o CAI (codon adaptation index (codonw.sourceforge.net)) 
o PROTEIN.LENGTH (number of AAs in protein) 
o CODON.BIAS (codon bias index (codonw.sourceforge.net)) 
o PCT.ALA 
o PCT.ARG 
o PCT.ASN 
o PCT.ASP 
o PCT.CYS 
o PCT.GLN 
o PCT.GLU 
o PCT.GLY 
o PCT.HIS 
o PCT.ILE 
o PCT.LEU 
o PCT.LYS 
o PCT.MET 
o PCT.PHE 
o PCT.PRO 
o PCT.SER 
o PCT.THR 
o PCT.TRP 
o PCT.TYR 
o PCT.VAL 
o FOP.SCORE (frequency of optimal codons (codonw.sourceforge.net)) 
o GRAVY.SCORE (hydropathicity of protein) 
o AROMATICITY.SCORE (Frequency of aromatic amino acids: Phe, Tyr, 
Trp) 
o VERIFIED (1 if Verified, 0 if Uncharacterized or Dubious ORF) 
 
• PRD.LLK (Prion-like AA comp score form earlier version of PLAAC) 
• FInumaa (FoldIndex: number of disordered residues) 
• FImeanhydro (FoldIndex: mean hydropathy score) 
• FImeancharge (FoldIndex: mean charge) 
• FImeancombo (FoldIndex: disorder score for whole protein) 
• FImaxrun (FoldIndex: longest run of consecutive disorder) 
• IUcount (IUpred: number of disordered residues) 
• IUmaxrun (IUpred: longest run of consecutive disorder ) 
• IUmean (IUpred: mean of per-residue disorder scores) 
• ANCHORcount (ANCHOR: number of disordered binding regions) 
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• ELMcount (number of Eukaryotic Linear Motifs) 
 
• 1 for Gene Ontology membership in following categories, 0 otherwise 
o GO.regulation.of.biological.process  (GO:0050789) 
o GO.transcription (GO:0006350) 
o GO.signaling (GO:0023052) 
 
• From BIOGRID 2.0.5.29 
o Essential (1 if gene deletion is toxic (need ref; hom or het?)) 
o y2h.total (total number interactions by Y2H (from BIOGRID 2.0.5.29)) 
o y2h.unique (number of distinct proteins with Y2H interaction) 
o y2h.essential.total (total number of interactions with essential proteins by 
Y2H) 
o y2h.essential.unique (number of distinct essential proteins with Y2H 
interaction) 
o count.het.sensitive (number of conditions in which heterozygous deletion 
was sensitive) 
o count.hom.sensitive (number of conditions in which homozygous deletion 
was sensitive (ref?)) 
o TAP.FILTERED (protein filtered out from TAP interactome (for being too 
sticky?) 
o count.sga.hits (number of synthetic genetic associations (Costanzo and 
Boone 2009) 
o sga.universe (if part of universe of tested genes in above study) 
o HAS.HUMAN.ORTH (1 if protein had human ortholog, 0 otherwise) 
o HAS.DISEASE.ORTH (1 if protein had human ortholog associated with 
OMIM disease, 0 otherwise) 
 
• The following features are from Vavouri et al Cell 2009 
http://www.cell.com/cms/attachment/604186/4784523/mmc1.pdf 
o Dosage.sensitive        ## Toxic due to overexpression in Sopko et al 2006 
o Intrinsic.Disorder..GlobPlot. 
o Intrinsic.Disorder..DisEMBL.REM. 
o Intrinsic.Disorder..DisEMBL.COILS. 
o Number.of.binary.protein.interactions 
o 5..UTR.length..bp. 
o Translation.rate 
o Upstream.conservation..fraction. 
o Transcription.rate 
o Protein.half.life..mins. 
o Upstream.noncoding.region..bp. 
o mRNA.half.life..mins. 
o Protein.abundance 
o Aggregation.load 
o 3..UTR.length..bp. 
o Aggregation.score..TANGO.score. 
o Responsiveness 
o Noise..DM. 
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o Aromaticity.score 
o Expression.divergence 
o Recombination.rate 
o Number.of.protein.complex.interactions 
o Frequency.of.optimal.codons 
o mRNA.abundance 
o Codon.bias 
o Ka.Ks 
o Underwrapping 
 
4.4 Immunoblotting 
Yeast were grown to logarithmic growth phase in synthetic media with raffinose, 
then pelleted by centrifugation, resuspended in galactose-containing media, and 
incubated overnight (16 hours) at 30 ºC with rotation. Cultures were pelleted, washed 
with sterile water, and treated with 0.05 M NaOH for 10 min at room temperature. Yeast 
suspensions were pelleted and then resuspended in sample buffer (60mM TrisHCl, pH 
6.8, 5% glycerol, 2% SDS 200, 4% beta-mercaptoethanol, 0.0025% bromophenol blue) 
and boiled for 5 minutes. Cleared lysates were separated by SDS-PAGE (Bio-Rad Cat. 
No. 3450010 Criterion Tris-HCl Precast Gels, 4–20% gradient) and transferred onto a 
PVDF membrane (EMD Millipore IPFL00010 Immoblilon-FL) by semi-dry transfer (BIO-
RAD Cat. No. 1703940). Membranes were blocked (Odyssey 927-40000 PBS Blocking 
Buffer) overnight at 4’C. Primary antibodies were diluted in blocking buffer and incubated 
with blots for 1 hour at room temperature with rocking. Blots were washed 4 times for 10 
minutes in PBS-T (0.01 M phosphate buffer, pH 7.4, 0.0027 M potassium chloride, 0.137 
M sodium chloride, 0.1% Tween-20) and incubated with secondary antibodies for 1 hour 
at room temperature with rocking. Blots were washed 4 times for 10 minutes in PBS-T, 
twice for 5 minutes in PBS. Blots were visualized using LI-COR Odyssey Model 9120 or 
Fc Imaging systems and analyzed with LI-COR Image Studio software. 
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Antibodies used were:  
• anti-Hemagglutinin (HA) monoclonal (Roche 11583816001, 0.4µg/ml final 
concentration) 
• anti-Hsc82 (Abcam ab30920, 1:1000) 
• anti-Hsp70 (Abcam) 
• anti-TDP-43 polyclonal (Proteintech 10782-2-AP, 1:1000) 
• anti-FUS polyclonal (Bethyl A300-302A, 1:2000) 
• anti-Hsp104 polyclonal (Enzo Life Sciences ADI-SPA-1040, 1:1000) 
• anti-3-phosphoglycerate kinase (Pgk1) monoclonal (Novex Part# 459250, 
1:1000) 
• anti-Src antibody (Abcam ab16885, 1:250) 
• anti-phosphotyrosine (Millipore 05-321, 1:1000) 
• IRDye680RD Donkey Anti-Rabbit (LICOR 926-68073, 1:7500) 
• IRDye800CW Donkey Anti-Mouse (LICOR 925-32212, 1:7500) 
4.5 Semi-denaturing Detergent Agarose Gel Electrophoresis (SDD-AGE) 
SDD-AGE was conducted with modification as reported (Halfmann, JoVE 2008). 
The HA-tagged proteins were transformed into BYV, BYW, and BYA yeast. 
Transformants were grown in Raffinose-containing synthetic media to logarithmic growth 
phase in 96-well deepwell plates (Eppendorf Cat. No. 0030502302), then yeast were 
pelleted by centrifugation (1500 g for 5 minutes) and resuspended in Galactose-
containing synthetic media at an optical density (OD600) of 0.100. Following overnight (16 
hour) induction, yeast were pelleted by centrifugation, washed with sterile water, 
pelleted, and then resuspended in spheroplasting solution (1.2 M D-sorbitol, 0.5 mM 
MgCl, 220 mM Tris, pH 7.5, 50 mM β−ME and 0.5 mg/ml Zymolyase 100T) and 
incubated for 1 hour at 30˚C with occasional shaking to keep the yeast suspended in 
solution. Spheroplasts were pelleted by centrifugation (500 rcf for 5 minutes) and 
resuspended in lysis buffer (100 mM Tris, 7.5, 500 mM NaCl, and 1% Protease Inhibitor 
cocktail (Sigma P8215), 2mM EDTA, and 2mM PMSF). The suspensions were vortexed 
at high speed for 1 minute and then snap-frozen in liquid nitrogen. 4X sample buffer (2X 
TAE, 20% glycerol, 2 or 8% SDS, 10% β−ΜΕ, and 0.0025% bromophenol blue) was 
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added to lysates and incubated for 5 minutes at room temperature. Samples were 
loaded onto a 1.5% Agarose gel in 1X TAE and 0.5% or 2% SDS in a horizontal slab 
electrophoresis apparatus tray. Samples were run at 5 V per cm of terminal distance in a 
4 ºC cold room until dye front was 1.5 cm from the end of the gel. The samples were 
then transferred by vertical capillary action overnight onto a nitrocellulose membrane as 
reported (Halfmann, JoVE 2008). The membranes were blocked overnight in Licor 
Blocking Buffer and then incubated with anti-HA monoclonal primary diluted in blocking 
buffer (1:1000) for 1 hour, washed 4 times in PBS-T for 10 minutes each, incubated with 
anti-Mouse IRDye 800CW secondary antibody in blocking buffer (1:7500) for 1 hours, 
washed 4 times for 10 minutes in PBS-T, twice for 5 minutes in PBS. Proteins were 
detected LI-COR Odyssey Models 9120 and Fc and analyzed with LI-COR Image Studio 
software. 
4.5 Filter Retention Assay 
Lysates from yeast expressing HA-tagged proteins were prepared as for SDD-
AGE. 4X sample buffer (2X TAE, 20% glycerol, 0.4% SDS, 10% β−ΜΕ, and 0.0025% 
bromophenol blue) was added to lysates and incubated for 5 minutes at room 
temperature. Samples were applied onto two stacked membranes using a Minifold I 96 
well spot-blot array system (GE Healthcare 10447850): on top, the 0.2µm pore size 
cellulose acetate (Whatman OE66 Cat No. 10404129) that bound large aggregates with 
0.45µM nitrocellulose membrane (Thermo 88018) below to bind protein flowthrough. A 
piece of Whatman 3MM CHR (GE Healthcare 3030-221) filter paper was placed on the 
bottom of the stack to facilitate sealing of each well. 20-100 µl of prepared lysates were 
applied directly to the membranes. Care was taken not to over load the membranes and 
thus disrupting flow of sample and wash buffer through the membrane. While still in the 
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spot-blot apparatus, each sample well on the membrane was washed three times with 
200 µl PBS-T. The blots were removed from the apparatus and washed again with PBS-
T for 10 minutes with rocking and then blocked with Odyssey Blocking Buffer (PBS) 
overnight at 4 ºC with rocking.  Next, the blots were incubated with anti-HA monoclonal 
primary diluted in Licor Blocking Buffer (1:1000) for 1 hour at room temperature with 
rocking. After four 10-minute washes in PBS-T with rocking, membranes were incubated 
with anti-Mouse IRDye 800CW secondary antibodies in Licor Blocking Buffer (1:7500) 
for 1 hour at room temperature with rocking. Membranes were washed 4 times for 10 
minutes in PBS-T, twice for 5 minutes in PBS, all with rocking, and finally visualized 
using LI-COR Odyssey Model 9120 or Fc Imaging systems and analyzed with LI-COR 
Image Studio software. 
4.6 Generation of yeast deletion strains (with Korrie Mack) 
PCR-based gene disruptions was performed to knockout Hsp104 from BY4741-
based atg8Δ and rpn4Δ yeast strains (Dharmcon YSC6273-201930575, YSC6273-
201935103, YSC6273-201921616 respectively). Forward and reverse primers were 
designed with 5’ overhangs that were complementary to the ORF of the Hsp104 gene 
and a 3’ section that were complementary to Hygromycin B phosphotranferase gene. 
PCR-amplification was used to produce a DNA fragment that was transformed into yeast 
that utilized homologous recombination to replace the Hsp104 ORF with the Hygromycin 
B phosphotransferase gene. Transformants were plated on YPD agar with 300 µg/ml 
Hygromycin B to select for yeast with the gene insertion. PCR was used to confirm gene 
disruption and Western blot analysis used to determine loss of Hsp104 expression. 
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4.7 Ppz1 Protein Purification 
GST-PPZ1 and GST-PPZ1R451L were purified from BL21-CodonPlus(DE3)-RIL E. 
coli (Agilent Cat. No. 230245) as reported with modifications (275). Briefly, bacteria 
transformed with the pGEX6P1-PPZ1 or pGEX6P1-PPZ1R451L were grown in LB with 0.5 
mM MnCl2 at 37 ºC with rotation overnight. The following day, the cultures were diluted 
in LB with 0.5 mM MnCl2 and incubated at 37 ºC with shaking (250 rpm) to OD600 0.4. 
Cultures were then chilled to 15 ºC and induced with 0.5 mM IPTG overnight, 
approximated 16 hours. Cells were pelleted by centrifugation, resuspended in 10 pellet 
volumes sonication buffer (50 mM Tris-HCl, pH 7.5, 0.2 mM EGTA, 150 mM NaCl, 10% 
glycerol, 0.1% Triton X-100, 2 mM dithiothreitol, 2 mM phenylmethylsulfonyl fluoride, and 
cOmplete protease inhibitor cocktail (Roche Cat. No.11836153001)). Cell suspensions 
were sonicated three times for 30 seconds with 90% power on ice. Lysates were clarified 
by centrifugation (20 minutes, 16,000 rcf) and the supernatant was bound to sonication 
buffer equilibrated Glutathione Sepharose (GE Healthcare 17075601) for 2 hours at 4 ºC 
with rotation. Resin was washed with 30 resin volumes of sonication buffer and GST-
fusion proteins were eluted with 20mM Glutathione in sonication buffer. Eluted protein 
was buffer exchanged into cleavage buffer (50 mM Tris HCl, pH 8.0, 100 mM NaCl, 1 
mM EGTA, 1 mM DTT). To cleave GST moiety, 2 units Prescission Protease (GE 
Healthcare 27-0843-01) were added for every 100 mg of eluted protein and incubated 
for 4 hours at 4 ºC. The cleavage reaction was then incubated to cleavage buffer 
equilibrated Glutathione Sepharose for 30 minutes to removed cleaved GST and 
Prescission Protease, which is also GST-tagged. Elution fractions were pooled and 
concentrated to 3 mg/ml. 
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4.8 Ppz1 Phosphatase Assay  
0.7 µM purified Ppz1 or Ppz1R451L was mixed with either 2.1 µM hexameric 
Hsp104 or Hsp104A503S (purified as reported)(207) and 4 mM ATP (pH 7.5) in Buffer A 
(20 mM Tris-HCl pH 7.5, 100 mM KCl, 5 mM DTT, 0.1 mM EGTA, 10% glycerol, 20µg/ml 
BSA, 0.005% Triton X-100, 10 mM MnCl2). 10mM pNPP reagent was added, at the 
concentration recommended in manufacturer instructions (BioAssay Systems Cat. No. 
POPN-500). Absorbance at 405nm was measured every 30 seconds for 15 minutes by 
Tecan Safire2 at room temperature. 
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